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Limits on Hard-to-Reproduce Inventions:
Process Elements and Biotechnology's
Compliance with the Enablement
Requirement
By DMITRY KARSHTEDT, PH.D.
I. Introduction
Reproducibility is the touchstone of the scientific method and
one of the strongest norms of the research community.' In order to be
accepted as scientific fact, results of an experiment must be
reproducible by an independent operator following the description
given by the original inventor.2 The inability of others to reproduce
results described in a scientific publication can often ruin a scientist's
reputation because the lack of reproducibility or operability of
published procedures can be evidence of sloppiness or outright
fabrication. One of the formal penalties for publishing
unreproducible or inoperable research is a forced retraction of a
publication, or at least a correction that accurately describes the
* Third-year law student, Stanford Law School. Dr. Karshtedt was born in Moscow
and moved to the United States when he was 12. He graduated from Lowell High School
in San Francisco, Harvard College, and the University of California at Berkeley, where he
received his Ph.D. in organometallic chemistry in 2005 under the supervision of Professor
T. Don Tilley. Before attending law school, Dr. Karshtedt worked for over two years as a
staff scientist at Kovio, Inc., a Silicon Valley startup involved in the development of
semiconductor materials. He has published five scientific papers in peer-reviewed journals
and is the first named inventor on a pending patent application.
Dr. Karshtedt would like to thank Robin Feldman, Hank Greely, Scott Kieff, Mark
Lemley, and Dr. Roberta Morris for many helpful comments and Carol Brass and John
Williams for editorial suggestions.
1. Michael C. H. McKubre, THE IMPORTANCE OF REPLICATION, in ICCF-14
INTERNATIONAL CONFERENCE ON CONDENSED MATTER NUCLEAR SCIENCE 1 (2008)
(internal quotations omitted).
2. IUPAC COMPENDIIM OF CHEMICAL TERMINOLOGY 567 (2d ed. 1997).
3. See, e.g., Kenneth Chang, Columbia Chemistry Professor Is Retracting 4 More
Papers, N.Y. TIMES, June 15, 2006.
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published experiment.' Occasionally, researchers who author
unreproducible experiments can be stripped of their doctoral degrees.
However, this remedy is generally limited to cases involving evidence
of fraudulent behavior.! These penalties underscore the importance of
the reproducibility norm in the research community.
Verifiability is closely bound to reproducibility. The concept of
verifiability has a long pedigree in the philosophy of science, but, for
the purposes of this Article, I will adopt a functional, in-the-trenches
definition of verifiability. Simply, verifiability is the ability of a
follow-on researcher to confirm that he or she has successfully
reproduced the original experiment. In scientific publications that
describe syntheses of chemical compounds, for example, the original
researcher is typically required to provide enough data to
characterize the published compounds. The characterization
requirement compels the original researcher to give evidence
supporting his or her results and benefits other researchers in the
field by empowering them to confirm that they have made the same
compound as the pioneering worker.' If analytical techniques for
positively identifying the compound could not be employed or were
not available, the researcher must indicate this deficiency in the
publication and describe possible ambiguities in the structure of the
compound. The inability to provide data that positively identify a
chemical compound can result in the rejection of a publication during
the peer review process.' For certain inorganic compounds, for
example, the absence of a crystal structure can often bar publication
in a prestigious journal because reviewers or editors do not really
4. See Chang, supra note 3.
5. See generally EUGENIE SAMUEL REICH, PLASTIC FANTASTIC: HOW THE
BIGGEST FRAUD IN PHYSICS SHOOK THE SCIENTIFIC WORLD (2009).
6. See, e.g., Rudolph Carnap, Testability and Meaning, in READINGS IN
PHILOSOPHY OF SCIENCE (Herbert Feigl & May Brodbeck eds., 1953).
7. See, e.g., Guidelines for Characterization of Inorganic and Organometallic
Compounds, JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, http://pubs.acs.org/
page/jacsat/submission/inorg-character.html ("Only in exceptional circumstances will a
paper be published in which none of the new compounds reported has been isolated and
fully characterized.").
8. See JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, Ethical Guidelines to
Publication of Chemical Research, in AMERICAN CHEMICAL SOCIETY PUBLICATIONS 1, 2
(2006), available at http://pubs.acs.org/userimages/ContentEditor/1218054468605/
ethics.pdf ("An author's central obligation is to present an accurate account of the
research performed" and that "[a] primary research report should contain sufficient
detail . . . to permit the author's peers to repeat the work.").
9. See id.
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"believe" the result."' The chemistry community enforces the
requirement of verifiability by mandating positive characterization of
published compounds because it strives to ensure that published
research is well-supported and reproducible. The added virtue of
verifiability is that it allows follow-on researchers to confirm the
identity of a published compound even if they make it by a route
different from that described in the original publication. Thus, for
example, a chemist can use the available identification data to prove
that a compound he or she has synthesized in the laboratory is exactly
the same as that extracted from a plant or animal source."
U.S. patent law does not directly mandate reproducibility or
verifiability as requirements for patentability, but it does recognize
their importance by requiring that the specification of a patent teach
others skilled in the art to practice the patented invention.12 Section
112 of the Patent Act states, in relevant part:
The specification shall contain a written description of the
invention, and of the manner and process of making and using
it, in such full, clear, concise, and exact terms as to enable any
person skilled in the art to which it pertains, or with which it is
most nearly connected, to make and use the same .....
Courts have held that, if a person skilled in the art must engage
in "undue experimentation" to make and use the patented invention,
the patent would be found invalid for lack of enablement.1 Under
10. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, supra note 8 ("In many cases,
X-ray diffraction may provide the most unambiguous characterization of [inorganic
compounds]").
11. See Frank E. Koehn & Guy T. Carter, The Evolving Role of Natural Products in
Drug Discovery, 4 NAT. REVS. DRUG DISCOVERY 206 (2005); see also infra note 129 and
accompanying text.
12. 35 U.S.C. § 112 (2008).
13. Id. Note that enablement is determined as of the time of the filing. See MANUAL
OF PATENT EXAMINING PROCEDURE (8th ed. Rev. 7, July 2008) [hereinafter "MPEP"]
§ 2164.01 ("Any analysis of whether a particular claim is supported by the disclosure in an
application requires a determination of whether that disclosure, when filed, contained
sufficient information regarding the subject matter of the claims as to enable one skilled in
the pertinent art to make and use the claimed invention.") (emphasis added).
14. See, e.g., Genentech, Inc. v. Novo Nordisk, AS, 108 F.3d 1361, 1365 (Fed. Cir.
1997) (quoting In re Wright, 999 F.2d 1557, 1561 (Fed. Cir. 1993)). A number of
underlying factual inquiries, including (1) the quantity of experimentation necessary, (2)
the amount of direction or guidance provided, (3) the presence or absence of working
examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill
of those in the art, (7) the predictability or unpredictability of the invention, and (8) the
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this standard, patents that claim unreproducible or inoperable results
are, a fortiori, invalid for lack of enablement, for others skilled in the
art cannot practice the invention." One court described the undue
experimentation doctrine as a tool for invalidating patents and
screening out patent applications disclosing results that are
"unpredictable and unreliable."" This doctrine is consistent with the
disclosure17 and public notice8 functions of the patent document.
Indeed, inventors who try to patent an unreproducible invention or
whose specification" is inoperable fail to hold up their end of the
bargain inherent in the patent system.2' A patent containing such a
non-enabling disclosure is of very little value to the public.2
Moreover, if the specification does not provide enough information
for follow-on researchers of ordinary skill in the art to verify that
what they have made is identical to the claimed product, the notice
breadth of the claims, are made in order to conclude whether the experimentation is
undue. See In re Wands, 858 F.2d 731, 735, 736-37 (Fed. Cir. 1988).
15. On these facts, the USPTO may also reject claims under 35 U.S.C. § 101 as
lacking operable utility. See, e.g., In re Swartz, 232 F.3d 862 (Fed. Cir. 2000). Note that a
rejection of a claim for lack of enablement under 35 U.S.C. § 112 1 1 can be a corollary of
a § 101 operable utility rejection. See MPEP §§ 2107.02, 2164.07.
16. Wands, 858 F.2d at 735.
17. See Subhashini Chandrasekharan, Sapka Kumar, Cory M. Valley & Arti Rai,
Proprietary Science, Open Science and the Role of Patent Disclosure: The Case of Zinc-
Finger Proteins, 27 NAT. BIOTECHNOLOGY 140, 142-43 (2009); Jeanne C. Fromer, Patent
Disclosure, 94 IOWA L. REV. 539, 553 (2009) ("The accepted understanding in patent
policy and doctrine is that disclosure of a patented invention to the public-and its
dedication to the public after the expiration of the patent term-is part of a quid pro quo
the patentee must provide to gain the broad patent right.") (citations omitted); see also
Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141, 150-51 (1989). But see
Timothy R. Holbrook, Possession in Patent Law, 59 S.M.U. L. REV. 123 (2006) (arguing
that the patent document serves primarily to show that the inventor has possession of the
claimed invention).
18. See Tun-Jen Chiang, Fixing Patent Boundaries, 108 MICH. L. REV. 523, 529 (2010)
(discussing "the public notice function of claims"); Kelly A. Casey, Patent Hermeneutics:
Form and Substance in Claim Construction, 59 FLA. L. REV. 333 (2007); Clarisa Long,
Patent Signals, 69 U. CHI. L. REV. 625 (2002); see also Holbrook, supra note 17, at 149-50.
19. Technically, "specification" refers to both the claims and the written description
of the patent. However, use of the term "specification" to refer to the part of the patent
document other than the claims is now common, and I use "specification" in this sense.
20. See Orin S. Kerr, Rethinking Patent Law in the Administrative State, 42 WM. &
MARY L. REV. 127 (2000).
21. Perhaps, however, such a patent has some limited value in informing the public of
what does not work.
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function of the patent document is not fulfilled. 2  Without adequate
indicia of verifiability, follow-on researchers have no way of knowing
if they infringe the patent's claims.
There is another, related way in which patent law pays heed to
the norm of reproducibility and the concomitant requirements of
operability and verifiability. In order for a patent claim to be
properly rejected for failing to satisfy the novelty requirements of
§ 102 of the Patent Act, the potentially anticipatory prior art must
contain an enabling disclosure.2 To determine whether prior art is
enabling, courts deploy the undue experimentation inquiry used for
ascertaining compliance with the § 112 1 enablement requirement.24
How does this requirement apply in practice to the chemical arts?
The Manual of Patent Examining Procedure states that "a reference
does not contain an enabling disclosure if attempts at making the
compound or composition were unsuccessful before the date of the
invention."2 An applicant can, therefore, counter an examiner's
§ 102 (novelty) rejection of a claim by producing evidence of trying
and failing to practice (i.e., successfully perform) experiments
according to the instructions given in the prior art.26  Thus,
22. For general accounts of fundamental difficulties encountered in ascertaining what
claims mean, see Dan L. Burk & Mark A. Lemley, Fence Posts or Sign Posts? Rethinking
Patent Claim Construction, 157 U. PA. L. REV. 1743 (2009); Jeffrey A. Lefstin, The Formal
Structure of Patent Law and the Limits of Enablement, 23 BERKELEY TECH. L.J. 1141
(2008); Mark A. Lemley, The Changing Meaning of Patent Claim Terms, 104 MICH. L.
REV. 101 (2005). See also supra note 18.
23. See United States v. Adams, 383 U.S. 39, 50 (1966) ("An inoperable invention or
one which fails to achieve its intended result does not negative novelty."); PPG Indus., Inc.
v. Guardian Indus. Corp., 75 F.3d 1558, 1566 (Fed. Cir. 1996) ("To anticipate a claim, a
reference must disclose every element of the challenged claim and enable one skilled in
the art to make the anticipating subject matter."). Courts have applied the "undue
experimentation" standard to enablement by anticipatory art. See, e.g., Elan Pharms., Inc.
v. Mayo Found. for Med. Educ. & Research, 346 F.3d 1051, 1054 (Fed. Cir. 2003).
24. See supra note 23. To be sure, the standards for enablement under § 112 and
enablement by anticipatory prior art under § 102 are not identical. For example, the
potentially anticipatory reference does not have to disclose any utility in order to be
enabling for the purposes of anticipation. See Rasmusson v. SmithKline Beecham Corp.,
413 F.3d 1318, 1326 (Fed. Cir. 2005) (stating that "a prior art reference need not
demonstrate utility in order to serve as an anticipating reference under section 102").
25. MPEP § 2121.02.
26. See, e.g., In re Wiggins, 488 F.2d 538 (C.C.P.A. 1973). The applicant may convey
information about trying and failing to reproduce prior art experiments to the USPTO in a
"Rule 132" affidavit. 37 C.F.R. § 1.132 (West 2010). For an example of a Rule 132
affidavit, see U.S. Pat. App. No. 11/867,587, Amendment and Request for Reconsideration
after Non-Final Rejection, at 28-33 (filed July 14, 2009).
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reproducibility and operability bear directly on the determination of
whether prior art contains an enabling disclosure.
Of course, patentability requirements differ in many significant
respects from those of scientific publications. For one thing, a
scientific publication typically has to describe an actually completed
experiment, while a patent specification does not. A detailed
experimental description followed by "prophetic examples" can
satisfy the enablement requirement, even if no laboratory work has
taken place. Thus, a polymer chemist can patent a method of
polymerizing ethylene with a novel catalyst and include a prophetic
example describing, for instance, predicted molecular weight and
viscosity characteristics of a polymer that the catalyst is expected to
produce. Many commentators have bemoaned these so-called paper
patents and the resulting disconnect between scientific and legal
norms; some have called for a return to, or at least greater use of, the
"working prototype" model of enablement, by which an inventor
would have to provide evidence of actual reduction to practice to the
United States Patent and Trademark Office (USPTO).2
Nevertheless, such patent reform may deprive the world of valuable
inventions. 29  After all, once it is confirmed that a predicted
experiment in a paper patent works as described and produces the
claimed results without undue experimentation, the rest of the world
will benefit from the disclosure." Indeed, perfect correspondence
between the reproducibility norm and the statutory enablement
requirement is neither practical nor desirable, and courts have
27. See Atlas Powder Co. v. E.I. du Pont De Nemours & Co., 750 F.2d 1569, 1577
(Fed. Cir. 1984).
28. See, e.g., Christopher A. Harkins, Fending off Paper Patents and Patent Trolls: A
Novel 'Cold Fusion' Defense Because Changing Times Demand It, 17 ALB. L.J. SC. &
TECH. 407 (2007); Sean B. Seymore, Heightened Enablement in the Unpredictable Arts, 56
UCLA L. REV. 127 (2008).
29. A more prosaic reason to oppose such reform is that it may not lead to cost-
effective use of the USPTO's resources. See generally Mark A. Lemley, Rational
Ignorance at the Patent Office, 95 Nw. U. L. REV. 1495 (2001).
30. One commentator suggested a procedural change in the prosecution of paper
patents, arguing that patentees who draft claims supported by prophetic examples must
bear the burden of demonstrating enablement. See Seymore, supra note 28, at 156
("While the lack of working examples would not absolutely preclude patentability, in
order to rebut the prima facie case, the applicant would have to show that the specification
provides some technique which enables the scope of protection sought by the claims,
unless such knowledge is reasonably accessible to the PHOSITA.") (citation omitted). As
the law stands now, the burden is on the USPTO to demonstrate lack of enablement, even
for paper patents. See id.
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conceded as much. 1 There is a way, however, in which the
enablement requirement of patent law can become more closely
aligned with the norms of the research community. For patents
claiming subject matter that is inherently difficult to characterize and
verify, the law should encourage changes in claiming practice that
reflect the relatively low enabling value of the disclosure associated
with claims to such products. As explained above, some degree of
correspondence between reproducibility and patentability is
inevitable and necessary if patents are to serve their disclosure and
*33
notice functions.
This Article maintains that the enablement requirement of § 112
1, as informed by the reproducibility norm, calls for narrower claims
34*to some inventions in the biotechnological arts. In particular, this
31. See Amgen, Inc. v. Chugai Pharm. Co., Ltd., 927 F.2d 1200, 1212 (Fed. Cir. 1991),
cert. denied, 502 U.S. 856 (1991) ("What is required is an adequate disclosure of the best
mode, not a guarantee that every aspect of the specification be precisely and universally
reproducible.") While this statement refers to the best mode requirement of § 112 1, it
can apply with equal force to the enablement requirement.
32. Courts have looked to research norms for guidance in other areas of patent law.
For example, in In re Brana, 51 F.3d 1560 (Fed. Cir. 1995), the Federal Circuit relied partly
on the research community's expectations to hold that, for a claimed compound whose
asserted utility lies on in a pharmaceutical setting, in vitro testing is sufficient to satisfy
substantial utility requirements of § 101. "Usefulness in patent law, and in particular in
the context of pharmaceutical inventions, necessarily includes the expectation of further
research and development." Id. at 1569 (emphasis added). There is an active debate in
legal academia on what role scientific norms should play in patent law. See ROBIN
COOPER FELDMAN, THE ROLE OF SCIENCE IN LAW (2009); Rebecca S. Eisenberg,
Proprietary Rights and the Norms of Science in Biotechnology Research, 97 YALE L.J. 177
(1987); F. Scott Kieff, Facilitating Scientific Research: Intellectual Property Rights and the
Norms of Science: A Response to Rai & Eisenberg, 95 Nw. U. L. REV. 691 (2001); Arti
Kaur Rai, Regulating Scientific Research: Intellectual Property Rights and the Norms of
Science, 94 Nw. U. L. REV. 77 (1999). Of course, an important part of this debate, not
addressed here, is that the research community is not homogeneous, encompassing, for
example, academic and industrial research communities. Nevertheless, the goals of
reproducibility, operability, and verifiability are shared by all scientists.
33. See supra notes 12-24.
34. While claims can generally be supported with an adequate specification in order
to comply with the enablement requirement, the Supreme Court has recognized that the
problem can often reside in the claim itself. Thus, some overly broad claims simply cannot
be supported by the specification to overcome the challenge of invalidity:
While the cases more often have dealt with efforts to resort to specifications to expand
claims, it is clear that the latter fail equally to perform their function as a measure of the
grant when they overclaim the invention. When they do so to the point of invalidity and
are free from ambiguity which might justify resort to the specifications, we agree with the
District Court that they are not to be saved because the latter are less inclusive.
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Article makes the case for more frequent use of process limitations in
composition-of-matter (hereinafter, "composition") claims to
biological and biochemical inventions. The Court of Appeals for the
Federal Circuit (Federal Circuit) has very recently settled a long-
standing split of authority between two of its panels, holding in an en
banc opinion that process limitations m composition claims count for
the purpose of determining infringement." Thus, an accused product
has to embody all the elements of a composition claim, including a
process or source element if the claim has one, to infringe the claim.
Now that composition claims with process limitations have clear legal
significance, it is worth considering whether these claims are
appropriate for biotechnology inventions where the process of
preparing a claimed composition is intimately tied to the invention's
reproducibility and operability. For claims to compositions whose
properties or structures are highly process- or source-dependent,
process or source limitations may provide the most effective avenue
to ensure that those skilled in the art are enabled to practice "the full
scope of the claimed invention."
In Part I of this Article, I will discuss the primacy of the claim in
defining the patentee's legal rights and explain the jurisprudence of
product-by-process claims. Part I will also consider the implications
of the Sandoz decision, which clarified the legal status of claims with
process limitations in infringement analysis and created an apparent
divergence between novelty and infringement standards for such
claims." Part II will lay out the challenges for reproducibility and
verifiability of certain types of inventions in biotechnological arts,
particularly biosynthetic proteins. With references to shortcomings of
presently available analytical techniques and the problem of follow-
on biologics, this Part will consider when and whether adequate
Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 336 U.S. 271, 277 (1949); see also infra
Part II.
35. See infra Part I.B for a definition and discussion of process limitations.
36. Abbott Labs. v. Sandoz, Inc., 566 F.3d 1282, 1291 (Fed. Cir. 2009) (en banc).
37. Courts have generally placed both process and source elements in the same
category. See, e.g., Amgen Inc. v. F. Hoffmann-LaRoche, Ltd., 580 F.3d 1340, 1369-70
(Fed. Cir. 2009) (citing Sandoz for its holding on "process terms" and using the case to
analyze "source limitations" in one of the patents-in-suit). Note that I use "element" to
refer to parts of a claim whose legal status is unclear (e.g., process elements pre-Sandoz),
and "limitation" to refer to claim elements that have legal force in infringement analysis.
38. Sitrick v. Dreamworks, LLC, 516 F.3d 993, 1000 (Fed. Cir. 2008).
39. Sandoz, 566 F.3d at 1291.
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enablement of broad composition claims directed to such inventions
is possible. This Part will then argue for the appropriateness of a
regime that involves more frequent use of process limitations for
some inventions of biotechnology, with reference to the well-known
case of Amgen Inc. v. Hoechst Marion Roussel, Inc. 40 The focus of this
Part is to determine whether composition claims with process
limitations ensure compliance with the enablement requirement, as
examined through the lens of the reproducibility norm. Finally, Part
III will consider whether claims with process or source limitations
offer too little protection to the patentees, effectively limiting them to
claiming actual inventions and nothing more. This Part will also
suggest how the USPTO can ensure that patent applicants will use
process limitations when they are appropriate.
II. Process Elements as Enforceable Limitations on Patent
Claims
A. The Basics of Patent Claims
In U.S. patent law, claims define the scope of legal protection
that the federal government grants to the owner or exclusive licensee
of a patent.4' Judge Giles Rich of the Federal Circuit famously wrote
that "the name of the game is the claim" 42 and courts have followed
this maxim.4 Some commentators have argued that courts may
engage in overzealous interpretive efforts and, in so doing, undermine
the primacy of the claim by reading in limitations from the
specification.44 Nevertheless, claims remain the touchstone of
USPTO's determinations of patentability and of courts' rulings on
40. 314 F.3d 1313 (Fed. Cir. 2003).
41. 35 U.S.C. § 112 (2008) ("The specification shall conclude with one or more claims
particularly pointing out and distinctly claiming the subject matter which the applicant
regards as his invention."); see also 35 U.S.C § 154(a) (2008) (describing a patent as "a
grant to the patentee, his heirs or assigns, of the right to exclude others from making,
using, offering for sale, or selling the invention throughout the United States or importing
the invention into the United States").
42. Giles Sutherland Rich, Extent of Protection and Interpretation of Claims-
American Perspectives, 21 INT'L REV. INDUS. PROP. & COPYRIGHT L. 497,499 (1990).
43. See, e.g., In re Hiniker Co., 150 F.3d 1362, 1369 (Fed. Cir. 1998).
44. David Sanker, Note, Phillips v. AWH Corp.: No Miracles in Claim Construction,
21 BERKELEY TECH. L.J. 101, 101 (2006) (noting that "the court did not explain how to
read claims in light of the specification without importing limitations from the
specification into the claims").
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validity and infringement because "[t]he language of the claim frames
and ultimately resolves all issues of claim interpretation."4
The types of patent claims that one encounters roughly reflect
very general requirements of the Patent Act, which sets out
patentable subject matter as "any new and useful process, machine,
manufacture, or composition of matter, or any new and useful
improvement thereof...."4 6  Preambles of claims mirror these
statutory categories, as one frequently encounters process claims ("a
method for. . ."; "a process for. . ."), machine or device claims ("an
apparatus for. . ."; "a device comprising. . ."), and composition
claims ("a mixture comprising . . ."; "a compound having the
formula..."). The preamble is followed by claim elements or
limitations,7 which delimit the scope of the claim so that it satisfies
statutory novelty, 48 non-obviousness, 49 and disclosure"' requirements.
An example is helpful to illustrate how limitations work: In a claim
that reads, "a mixture comprising from about 80% to about 95% by
weight of polyethylene and from about 5% to about 20% by weight of
atactic polypropylene," the amounts and identities of polymers that
make up the mixture are the claim limitations. Because "[a] claim
covers an accused device if the device embodies every limitation of
the claim,"" a mixture that comprises 87% polyethylene and 13%
atactic polypropylene literally infringes our fictitious claim. A
mixture that comprises 85% polyethylene, 10% atactic
polypropylene, and 5% some other substance also infringes. In
contrast, a mixture that comprises 50% polyethylene and 50% atactic
polypropylene does not infringe. Also not infringing are mixtures
that comprise 87% polyethylene and 13% polybutylene or 87%
polyethylene and 13% isotactic polypropylene, since these
45. AbTox, Inc. v. Exitron Corp., 122 F.3d 1019, 1023 (Fed. Cir. 1997) (citing
Markman v. Westview Instruments, Inc., 52 F.3d 967, 979 (Fed. Cir. 1995) (en banc), aff'd,
517 U.S. 370 (1996)).
46. 35 U.S.C. § 101 (2008).
47. A preamble itself can, under certain circumstances, serve as a limitation. See
MPEP § 2111.02.
48. 35 U.S.C. § 102.
49. 35 U.S.C. § 103.
50. 35 U.S.C. § 112. Disclosure requirements are satisfied by the patent document as
a whole, i.e., by claims in conjunction with the specification.
51. Carroll Touch, Inc. v. Electro Mechanical Sys., Inc., 15 F.3d 1573, 1576 (Fed. Cir.
1993).
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compositions do not embody both polyethylene and atactic
polyproplyene limitations of the claim.
Chemical and biological inventions are typically claimed as
compositions, processes, or both. For example, a synthetic chemist
who makes a previously unknown molecule X can likely obtain claims
for both "a compound having formula X" and "a process for
synthesizing the compound having formula X." Composition claims
are considered to be much more powerful than process claims
because such claims may severely limit the ability of follow-on
researchers to design around the patented invention.52 Thus, one can
avoid infringing a process claim on a molecule by inventing a
different process for preparing the same molecule, but the same
strategy will not work for avoiding infringement of a composition
claim. The owner of a patent with composition claims can assert the
patent against an inventor who makes the molecule by another
process, even if the follow-on process is much more efficient.i For
example, the owners of an original patent on polypropylene, who
claimed "normally solid polypropylene," successfully asserted their
claims against subsequent researchers who synthesized the polymer
by methods that significantly improved on the methods used by the
patentees. In addition to a robust right to exclude generally
provided by composition claims,' patentees also favor such claims
52. See Jeanne F. Loring & Cathryn Campbell, Intellectual Property and Human
Embroynic Stem Cell Research, 311 SCIENCE 1716 (2006).
53. See generally Charles W. Adams, Allocating Patent Rights Between Earlier and
Later Inventions, 54 ST. Louis U. L.J. 55 (2009). Of course, a potential infringer can
escape liability by modifying the composition by designing around the claim such that the
new composition does not fall within the scope of the claim.
54. See United States Steel Corp. v. Phillips Petroleum Co., 865 F.2d 1247 (Fed. Cir.
1989). The liability of an improving inventor to the owner of the "dominant" patent is a
general feature of patent law, however, and is not limited to composition claims. See supra
note 53.
55. See 35 U.S.C. § 154(a), which describes patents as granting "the right to exclude
others from making, using, offering for sale, or selling the invention throughout the United
States." Any patent, not just one with composition claims, grants such a right to exclude,
but certain types of composition claims are seen as particularly powerful relative to other
types of claims, such as process claims. See Oskar Liivak, Maintaining Competition in
Copying: Narrowing the Scope of Gene Patents, 41 U.C. DAVIS L. REV. 177, 201-03, 230-
31 (2007); supra note 52 and accompanying text. But see Robert N. Sahr, The Biologics
Price Competition and Innovation Act: Innovation Must Come Before Competition, 2009
B.C. INTELL. PROP. & TECH. F. 070201, at *45 (2009) (suggesting that claims to certain
compositions are particularly susceptible to being designed around).
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because their infringement is typically easier to detect than that of
process claims.
B. Process Limitations on Composition Claims and the Sandoz
Decision
Given the potentially very broad coverage afforded to
composition claims, determination of appropriate limitations for this
type of a claim is particularly important. As indicated in the
polyethylene/polypropylene example above, one kind of a
composition claim limitation goes to the constituent parts of the
composition. Yet another kind of a limitation can be based on
physical or structural characteristics of the composition, such as glass
transition (or melting) temperature or crystallinity of a polymer. For
example, a claim may read, "crystalline polypropylene having glass
transition temperature of 130 oC or higher" (physical limitations in
italics). Functional limitations (e.g., "polyethylene capable of being
molded into a rigid container") can also be used, although courts have
sometimes been suspicious of claims containing only functional
limitations.
A special, rather controversial, type of a limitation that
sometimes occurs in composition claims is a process limitation, which
refers to the product by a process by which it was made; analogously,
a source limitation refers to the product by a source from which it was
derived." A composition claim with a process limitation has the
general form "a material prepared by a process comprising the steps
of..." or "product X obtained by process Y."" Similarly, a
composition claim with a source limitation has the form "product X
obtained from source Z." While these kinds of claims are considered
"pure" product-by-process claims (when no physical, structural, or
other types of limitations are used at all),o one also encounters claims
56. John M. Olin, The Disclosure Function of the Patent System (or Lack Thereof),
118 HARV. L. REV. 2007, 2015 (2005).
57. See, e.g., Fiers v. Revel, 984 F.2d 1164 (Fed. Cir. 1993); see also Paul M. Janicke,
The Crisis in Patent Coverage: Defining Scope of an Invention by Function, 8 HARV. J.L. &
TECH. 155 (1994).
58. See supra note 37.
59. ROGER SCHECHTER & JOHN THOMAS, PRINCIPLES OF PATENT LAW 213-14 (2d
ed. 2004).
60. Judge Newman of the Federal Circuit believes that only such pure or "true"
product-by-process claims should be called product-by-process claims. See Atlantic
Thermoplastics Co. v. Faytex Corp., 974 F.2d 1279, 1284 (Fed. Cir. 1992) (Newman, J.,
dissenting from the denial of rehearing en banc). I generally follow this approach in the
7 - KARSHIED1 11.19 (Do NoT DELETE) 11/20/2010 2:29 PM
WINTER 2011] HARD-TO-REPRODUCE INVENTIONS 121
of the form "product X having property M obtained by process Y" or
"product X having property N obtained from source Z.""
Until very recently, there was a split of authority in the Federal
Circuit as to whether process elements are legally effective for the
purpose of determining patent infringement. That is, it was unclear if
product X prepared by process Z literally infringes the claim to
"product X obtainable by process Y." One line of authority stemmed
from Scripps Clinic & Research Foundation v. Genentech, Inc. ,62 which
had held that the factual scenario described above warrants a finding
of infringement. The fundamental rationale for the Scripps decision
is predicated on the maxim that "claims must be construed the same
way for validity and for infringement."' Since it is well established
that a composition claim to a known product prepared by a new
process is invalid under § 102 of the Patent Act,64 the infringement-
validity maxim leads to the result, achieved by the Scripps panel, that
process elements should not limit the scope of a claim to a novel
product. That is, because process elements cannot impart novelty to
a composition claim directed to a known product, the Scripps panel
reasoned that such elements, when they are directed to a novel
product, should not constrain the reach of the composition claim in
infringement analysis. Scripps held: "[T]he correct reading of
product-by-process claims is that they are not limited to product
prepared by the process set forth in the claims."
Article, calling claims that have structural limitations in addition to process limitations by
a cumbersome, but descriptive moniker "composition claims with process limitations."
61. See Atlantic Thermoplastics Co., 974 F.2d at 1284.
62. 927 F.2d 1565 (Fed. Cir. 1991). For an excellent early account of the Scripps case
and the 1991 Amgen v. Chugai case (see infra note 131 and accompanying text), see
Michael S. Greenfield, Note, Recombinant DNA Technology: A Science Struggling with
the Patent Law, 44 STAN. L. REV. 1051, 1093 (1992) (concluding that "[i]nstead of product
patents, process claims constitute a more appropriate form of protection for naturally
occurring proteins."). For another set of views on these cases, see Bret Field, Note,
Protein Pharmaceuticals: Altering the Scope of Product Patents to Accommodate
Recombinant DNA Technology, 15 HASTINGS COMM. & ENT. L.J. 495 (1993).
63. Id. at 1583. This so-called infringement-validity maxim is sometimes stated as
follows: "that which would literally infringe if later in time anticipates if earlier." Schering
Corp. v. Geneva Pharms., Inc., 339 F.3d 1373, 1379 (Fed. Cir. 2003) (quoting Bristol-Myers
Squibb Co. v. Ben Venue Labs., Inc., 246 F.3d 1368, 1378 (Fed. Cir. 2001)).
64. See Atlantic Thermoplastics Co., Inc. v. Faytex Corp., 970 F.2d 834, 844 (Fed. Cir.
1992) ("An applicant could obtain a process patent for a new, useful, and non-obvious
process, but could not claim rights to a product already in the prior art by merely adding a
process limitation.").
65. Scripps, 927 F.2d at 1583.
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Another line of authority stemmed from Atlantic
Thermoplastics Co., Inc. v. Faytex Corp.," which had held that, if an
accused infringer of a composition claim with a process limitation can
show that the product was made by a different process, then no
finding of infringement is warranted. The fundamental rationale for
Atlantic Thermoplastics is that "infringement requires the presence of
every claim limitation or its equivalent" in the accused device or
product, and that the Scripps decision has the undesirable effect of
reading out a claim limitation.6 The Federal Circuit initially refused
to hear the Atlantic Thermoplastics case en banc to resolve the
apparent conflict between the Scripps and Atlantic Thermoplastics
panels, leaving district courts with the choice of which line of
authority to follow." After 17 years of uncertainty, the Abbott
Laboratories v. Sandoz, Inc. decision explicitly overruled Scripps and
affirmed Atlantic Thermoplastics, holding that process elements in
composition claims are effective as limitations in infringement
analysis.9
In Sandoz, the Federal Circuit heard a consolidated appeal of
two district court rulings that concerned brand-generic litigation
based on the generic manufacturers' Abbreviated New Drug
Applications (ANDAs).7) The lawsuits implicated Abbott's patent on
66. 970 F.2d 834.
67. Atlantic Thermoplastics Co., Inc., 970 F.2d at 846; see also at 838 n.2 (noting that
Scripps failed to consider Supreme Court precedent). But see Atlantic Thermoplastics
Co., Inc. v. Faytex Corp., 974 F.2d 1279, 1281 (Fed. Cir. 1992) (Rich, J., dissenting from
the denial of rehearing en banc) ("The most egregious act of the Atlantic panel ... is its
defiant disregard, for the first time in this court's nearly ten-year history, of its rule that no
precedent can be disregarded or overruled save by an en banc court, on the stated but
feeble ground that the authors of the precedential opinion 'ruled without reference to the
Supreme Court's previous cases involving product claims with process limitations.' ...
This is not only insulting to the Scripps panel .. ., it is mutiny. It is heresy. It is illegal.").
68. Atlantic Thermoplastics, 974 F.2d at 1279. Although Scripps, according to Federal
Circuit rules, should have been followed as the earlier of the two panel decisions, see id. at
1281 ("where there are conflicting [panel] precedents, the earlier precedent controls")
(emphasis in original), some district courts followed Atlantic Thermoplastics. For an early
case following Atlantic Thermoplastics, see Tropix, Inc. v. Lumigen, Inc., 825 F. Supp. 7
(D. Mass. 1993). For a case following Scripps, see Trs. of Columbia Univ. v. Roche
Diagnostics GmbH, 126 F. Supp. 2d 16 (D. Mass. 2000). For attempts to reconcile Atlantic
Thermoplastics and Scripps, see Atlantic Thermoplastics, 974 F.2d at 1281-98 (Newman, J.,
dissenting from the denial of rehearing en banc); Gregory S. Maskel, Product-by- Process
Patent Claim Construction: Resolving the Federal Circuit's Conflicting Precedent, 17
FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 115 (2006).
69. 566 F.3d 1282, 1291 (Fed. Cir. 2009) (en banc).
70. Id.; see 21 U.S.C. § 355(j) (2008) (detailing the law of ANDAs).
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a crystalline form of a chemical compound called cefdinir, a broad-
spectrum antibiotic marketed under the brand name Omnicef@ ,1 and
accused products made by two different generics manufacturers. The
first ruling, from the Eastern District of Virginia, was a declaratory
judgment action ending in summary judgment finding that defendants
did not infringe Abbott's patent, and the second, from the Northern
District of Illinois, was a denial of a motion for a preliminary
injunction based on the claim construction that led to the first ruling.
Abbott appealed both rulings and challenged the claim construction
that limited the scope of asserted cefdinir composition claims to a
specific crystalline form (Crystal A) of cefdinir, which is a
polymorphic compound (i.e., it can crystallize in several different
forms).74 The accused infringers manufactured a different crystalline
form of cefdinir, Crystal B. A Federal Circuit panel affirmed the
claim construction of the Eastern District of Virginia and upheld its
summary judgment ruling of non-infringement; likewise, the panel
upheld the Northern District of Illinois' denial of a preliminary
injunction. Although this was not necessary to resolve the
controversy, the court decided sua sponte to use the case as an
opportunity to lay down a definitive rule for proper interpretation of
composition claims with process limitations in the en banc part of the
opinion.
The claims in the '507 patent that contain processes limitations
deal with chemical subject matter. All three independent claims
(Claims 1, 2, and 5) are directed to a product called "crystalline 7-[2-
(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-
carboxylic acid (syn isomer)"; the terms after the word "crystalline"
represent the systematic chemical name for cefdinir. One additional
limitation in Claim 1 is simply a listing of peaks in the powder X-ray
71. U.S. Patent No. 4,935,507 (issued June 19,1990) ("the '507 patent").
72. Lupin Ltd. v. Abbott Labs., 491 F. Supp. 2d 563 (E.D. Va. 2007).
73. Abbott Labs. v. Sandoz, Inc., 486 F. Supp. 2d 767 (N.D. Ill. 2007).
74. See U.S. FOOD AND DRUG ADMINISTRATION, Scientific Considerations of
Polymorphism in Pharmaceutical Solids: Abbreviated New Drug Applications, http://www.
fda.gov/ohrms/dockets/ac/02/briefing/3900Bl04_Polymorphism.doc (last visited Nov. 26,
2009).
75. Sandoz, 566 F.3d at 1299.
76. Id. at 1294-95.
77. Cf SCHECHTER & THOMAS, supra note 59, at 214 (noting that "[product-by-
process] claims are most common in chemical practice").
78. '507 patent, col.16, 1. 13-34 & 43-50.
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diffraction (PXRD) spectrum of a specific crystalline polymorph of
cefdinir, Crystal A.79 Claims 2 and 5, however, include process
limitations that the court addressed in the en banc ruling. The subject
matter of Claim 2 is directed to cefdinir "obtainable by acidifying the
solution containing [the chemical precursor to cefdinir] at room
temperature or under warming.""' Claim 5 is directed to cefdinir
"obtainable by dissolving [the chemical precursor to cefdinir] in an
alcohol, continuing to stir the solution slowly under warming, then
cooling the solution to room temperature and allowing the solution to
stand."" Claims 3 and 4 depend from Claim 2, and are therefore
subject to the same analysis as Claim 2.
Before addressing the Sandoz analysis of process limitations in
detail, it is helpful to explain why the patentees likely chose to draft
the claims in this format. As it turns out, the patentees held another
patent on cefdinir,82 but the claims of the earlier patent did not specify
the crystallinity properties of the compound. Thus, crystallinity of the
cefdinir claimed in the '507 patent apparently helped bolster the
argument for novelty and non-obviousness of the subject matter of
the patent. The patentees did face a non-final obviousness (§ 103)
rejection of the claims of the '507 patent, with the examiner arguing
that "different forms of the same compounds are presumptively non-
patentable."" The applicants, however, countered by arguing that
"the crystalline form is unknown, unobvious, and productive of
unexpected advantageous results."8 4 The applicants emphasized that
"utility of [the] crystalline product is not the same as the utility of the
amorphous product of [the earlier patent]," including increased
potency and purity of the crystalline cedfinir relative to the
amorphous cefdinir disclosed in the prior art." The patentees also
79. PXRD is a standard analytical technique used to characterize crystalline
compounds, and peaks in a PXRD spectrum represent a "signature" of a specific
crystalline form of a chemical compound.
80. '507 patent, col. 16, 1. 29-34.
81. '507 patent, col. 16, 1. 43-50.
82. U.S. Patent No. 4,559,334 (issued Dec. 17, 1985) ("the '334 patent").
83. U.S. Pat. App. No. 07/229,489, Examiner's Action (Non-Final Rejection), at 2
(filed May 9, 1989).
84. U.S. Pat. App. No. 07/229,489, Amendment and Request for Reconsideration After
Non-Final Rejection, at 7 (filed Oct. 27, 1989).
85. Id. at 4 (emphasis in original). Note that properties of a chemical compound are
inseparable from its structure for the purpose of non-obviousness determinations. That is,
a compound whose structure is obvious in view of prior art may still be non-obvious under
§ 103 if it has unexpected properties. See In re Papesch, 315 F.2d 381, 391-92 (C.C.P.A.
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pointed out that the "method of preparation of the crystalline form of
the presently claimed compounds is not considered the heart of the
present invention. The crystalline form of the compound represents
the inventive concept thereof, and it is clear that [the earlier patent]
does not anticipate or suggest said crystalline form.""' Curiously,
however, the application as originally filed also included claims to
methods of synthesizing cefdinir (Claims 6-9) that paralleled the
composition Claims 2-5., In the examiner interview, the examiner
maintained the view that "claims 6-9 were substantial duplicates of 2-
5 and that cancellation of claims 6-9 would render the case
allowable.""
The en banc court did not reach the question of novelty or non-
obviousness of Claims 2-5, since the accused generic drug
manufacturers focused their defense on non-infringement (which, as
noted above," was successful even without resorting to the analysis of
process limitations). The court, with Judge Rader writing for the
majority, instead went on to clarify the infringement analysis of
product claims with process limitations and, relying on various
Supreme Court, Circuit Court, and Court of Customs and Patent
Appeals precedents, held that "the Eastern District of Virginia
correctly construed the process limitations beginning with 'obtainable
by' in claims 2-5 as limiting the asserted claims to products made by
those process steps."" Ultimately, the rationale of the en banc
majority was similar to that of the Atlantic Thermoplastics panel,
whose opinion was also authored by Judge Rader, as the court held
that the Scripps rule led to the impermissible result of reading
1963). A claimed compound (here, crystalline cefdinir) may be novel and non-obvious
even if falls into a previously disclosed genus. In re Baird, 16 F.3d 380, 382 (Fed. Cir.
1994). Here, the prior art patent disclosed (and claimed) cefdinir without any limitations.
See '334 patent, col. 20, 1. 21 (claim 2 encompassing crystalline cefdinir); see also infra note
105 and accompanying text.
86. U.S. Pat. App. No. 07/229,489, Amendment and Request for Reconsideration After
Non-Final Rejection, at 6 (filed Oct. 27, 1989) (emphasis added).
87. U.S. Pat. App. No. 07/229,489, Original Application, at 3 (filed Aug. 9,1988).
88. U.S. Pat. App. No. 07/229,489, Examiner Interview Summary Record (Nov. 14,
1989).
89. See supra notes 75-76 and accompanying text.
90. Sandoz, 566 F.3d at 1296. Note that the court did not perceive any legally
cognizable difference between the phrases "obtainable by" and "obtained by"-the
former was treated as equivalent to the latter in that it introduced a process limitation. Id.
at 1295.
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limitations out of claims.9' Judge Newman filed a scathing 20-page
dissent (with Judges Lourie and Mayer joining) with her own
assessment of the precedents cited by the majority, and argued that
applicants who are unable to claim a novel and non-obvious product
using structural or physical limitations should not be forced to seek
composition claims weakened by process limitations. 2 The dissent's
rationale was similar to that of Scripps, which Judge Newman wrote,"
as well as to her dissent from the denial of the rehearing en banc of
Atlantic Thermoplastics.9 In addition to noting that the Sandoz
holding violated the infringement-validity maxim,9 she argued against
the majority's rejection of the rule of necessity, which had given
patentees full composition claim protections when they did not have
enough information about their products to draft claims with
structural limitations.9' Another potential problem of the en banc
holding, as noted by Judge Newman, was that process-related phrases
that merely serve a definitional purpose may be read as limitations,
resulting in unwarranted narrowing of claim scope.97
Judge Lourie filed a separate dissent that characterized the
Supreme Court cases cited by the majority, some of which reached
back into the Nineteenth Century, as simply inapposite given the
difficulty of analogizing them to modern-day factual patterns
91. Sandoz, 566 F.3d at 1295 ("The process limitations cannot be haphazardly
jettisoned for an infringement analysis when they were so important in the patentability
analysis."); see also id. at 1294 ("Because the inventor chose to claim the product in terms
of its process, however, that definition also governs the enforcement of the bounds of the
patent right. This court cannot simply ignore as verbiage the only definition supplied by
the inventor.").
92. Id. at 1299-1320.
93. See supra notes 62-63 & 65 and accompanying text.
94. Atlantic Thermoplastics Co., Inc. v. Faytex Corp., 974 F.2d 1279, 1281-98 (Fed.
Cir. 1992) (Newman, J., dissenting from the denial of rehearing en banc).
95. See supra note 63 and accompanying text.
96. Sandoz, 566 F.3d at 1319 ("The purpose of the rule of necessity is to allow
inventors of complex new products to obtain the patent scope to which their invention is
entitled-the scope of the novel product they invented, no more and no less."). For more
on the rule of necessity, see Gary Newson, Note, Product-by-Process Patent Claims:
Arguing for a Return to Necessity and a Reduction in the Scope of Protection, 40 ARIZ. ST.
L.J. 327 (2008).
97. Sandoz, 566 F.3d at 1310-11 (citing MPEP § 2113). The issue of whether a
process-related phrase is definitional or truly limiting as a process element is a matter of
claim construction. See generally Eric P. Mirabel, Product-by-Process Claims: A Practical
Perspective, 68 J. PAT. & TRADEMARK OFF. Soc'y 3 (1986) and the discussion infra in
Part I.C; see also infra note 103.
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involving complex chemical and biotechnological inventions.
However, it must be added that the court did not rely exclusively on
very old cases. For example, the majority cited Warner-Jenkinson, a
relatively recent Supreme Court decision dealing with the doctrine of
equivalents, for the proposition that "[e]ach element contained in a
patent claim is deemed material to defining the scope of the patented
invention."
C. Why Use Process Limitations After Sandoz?
Given the apparently diminished level of protection afforded by
composition claims with process limitations (arguably after Atlantic
Thermoplastics and certainly after Sandoz), it is worth returning to
the question of why patentees may want to use such limitations at all.
According to Judge Newman, process-type limitations have been
used in three general types of scenarios. The first is a situation
"where the product is new and unobvious, but is not capable of
independent definition.""o" These circumstances force the use of what
Judge Newman called "true" product-by-process claims, where the
process limitation is the primary and perhaps the only limitation. 1o
The second scenario arises "when the product is old or obvious, but
the process is new." O2 In this case, the claim is best treated as a pure
process claim masking as a product claim, with no protection at all
afforded to the product. Finally, Judge Newman identified a third set
of circumstances, "when the product is new and unobvious, but has a
process-based limitation."")' This characterization implies that there
are non-process-based limitations in this type of a claim; the claim,
however, also includes process elements, which may serve a
definitional or a descriptive purpose, or may be necessary for
patentability.
98. Sandoz, 566 F.3d at 1320-21.
99. Id. at 1293 (quoting Warner-Jenkinson Co., Inc. v. Hilton Davis Chem. Co., 520
U.S. 17, 19 (1996)).
100. Atlantic Thermoplastics Co. v. Faytex Corp., 974 F.2d 1279, 1284 (Fed. Cir. 1992)
(Newman, J., dissenting from the denial of rehearing en banc).
101. Id.
102. Id.
103. Id. For this third type of claim, the very existence of a process limitation can be a
matter of claim construction. For example, verbs like "fluorinated," "molded," and
"bonded," can be read as introducing process-based limitations or as describing the
structure of the product. For an illuminating analysis of claim construction and other
issues in these types of claims, see Mirabel, supra note 97.
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Judge Newman's dissent from the rehearing en banc did not say
much about this third type of a claim, but it is perhaps the most
interesting of the three. While structural or other limitations can be
present in this hybrid claim, these limitations, by themselves, are
somehow deficient, and additional process-based limitations become
necessary. If one excludes sloppy claim drafting, some logical reasons
for introducing such limitations may involve improved prospects for
meeting novelty, non-obviousness, and/or disclosure requirements,
and perhaps even attaining a claim that affords broader coverage than
a corresponding claim with a highly restrictive structural limitation.
In both such cases, it stands to reason that process elements should
have the full legal force of a claim limitation, restricting claim scope in
infringement analysis.
In this light, it is instructive to examine the patent-in-suit in
Sandoz, because process limitations in two of the claims of that patent
could have been plausibly introduced to improve both prospects for
patentability and to increase scope of claim coverage relative to an
analogous structurally-limited claim. Independent Claims 2 and 5,
which contain process limitations, also include structural limitations-
the claims, after all, are to "crystalline 7-[2-(2-aminothiazol-4-yl)-2-
hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid (syn
isomer)." The chemical name of cefdinir refers to a precise,
structurally well-defined chemical entity, which is limited by the type
and arrangement of atoms that make up the cefdinir molecule;
"crystalline" further physically limits cefdinir to a specific
morphology. In the prior art patent, the same chemical compound
was disclosed and claimed (in Claim 2), but no physical property, such
as crystallinity or amorphousness, was described in the specification
or in the claim.104
It is likely that the patentees were concerned that, if they were to
try for a claim in the latter patent that read "Crystalline cefdinir,
period," the USPTO would consider it anticipated or obvious in view
of the prior art disclosure of the genus of "cefdinir." While precedent
exists that disclosure of a genus does not necessarily render a species
within the genus anticipated and/or obvious,"" it is unlikely that the
patentees would have been able to convince the examiner that the
entire "crystalline cefdinir" subgenus of "cefdinir," and not just the
104. '334 patent, col. 20,1. 21.
105. See In re Baird, 16 F.3d 380, 382 (Fed. Cir. 1994); In re Jones 958 F.2d 347, 350
(Fed. Cir. 1992).
7 - KARSHIEDT 11.19 (Do NoT DELETE) 11/20/2010 2:29 PM
WINTER 2011] HARD-TO-REPRODUCE INVENTIONS 129
species that they actually claimed, is patentable given the generic
cefdinir disclosure in the earlier patent. After all, given the research
they have done, the patentees could plausibly argue only that two
specific crystalline forms of cefdinir (Crystal A and Crystal B), which
they describe in the specification, offer unexpected potency and
stability properties."o' The patentees had no evidence that other
crystalline forms of cefdinir even existed, let alone had any beneficial
utilities. So, presumably to avoid a § 102 or § 103 rejection, the
patentees saw fit to limit the "crystalline cefdinir" genus to those
species produced by the two specific processes recited in Claims 2 and
5.11 In addition, in Claim 1, the patentees limited the "crystalline
cefdinir" genus to a species with a particular PXRD signature."'
It is not difficult to see that Claims 2 and 5 potentially afford
greater scope than Claim 1. After all, the PXRD data in Claim 1
clearly excludes Crystal B and explicitly limits the claim to Crystal A
because the claimed PXRD signature corresponds uniquely to Crystal
A of cefdinir."'9 In contrast, it is possible (and the patentees so argued
in the district court proceedings) that both Crystal A and Crystal B,
and maybe other cefdinir crystal morphologies, are covered by Claims
2 and 5, which have process limitations but do not constrain the
morphology of the claimed material to a unique crystal type. If it
turned out to be very difficult to produce crystalline forms of cefdinir
by other processes, Claims 2 and 5 would have been more powerful
than Claim 1, in spite of their process limitations! Of course, this issue
became moot when the Federal Circuit affirmed the district court's
claim construction that limited the scope of Claims 2 and 5 to only the
Crystal A form in view of a restrictive definition in the specification;
the accused generics manufacturers produced form B." "
Nevertheless, it is at least conceivable, in light of the prosecution
history of the '507 patent, that process limitations can be favorable to
patentees in terms of imparting novelty or non-obviousness to claims,
106. See supra notes 84-85 and accompanying text.
107. Cf Smithkline Beecham Corp. v. Apotex Corp., 439 F.3d 1312 (Fed. Cir. 2006)
(holding that product-by-process claims were anticipated by a patent on the underlying
product in spite of an apparent structural difference between the claimed product and the
prior art product).
108. See supra note 79 and accompanying text.
109. The patentees actually contested this conclusion, but the court found their
argument to be without merit. See Sandoz, 566 F.3d at 1289.
110. Id. at 1289-91.
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and potentially providing broader claim scope relative to highly
restrictive structural limitations.
While the above analysis illustrates that composition claims with
process limitations can be useful for complying with novelty and non-
obviousness requirements, this Article argues that such limitations
can also help patent applicants comply with the enablement
requirement of § 112 1. While applicants can often satisfy
disclosure requirements by submitting a sufficiently detailed
specification, an equally valid and sometimes the only strategy for
avoiding an enablement rejection by the USPTO, or a ruling of
invalidity for lack of enablement in litigation, is to narrow the scope
of the claims."' Indeed, narrowing of claims is appropriate where the
specification simply cannot support a broad composition claim so as
to ensure enablement of the "full scope of the invention." 112 in
particular, the third type of composition claim with process
limitations identified by Judge Newman," which contains some
structural and some process-based limitations, is uniquely appropriate
for claiming certain products of biotechnology.
III. Process Limitations for Products of Biotechnology
A. Chemical Composition Claim as an Infinite Genus of Processes
In order to demonstrate that process limitations appropriately
constrain the scope of claims directed to certain kinds of inventions, it
is instructive to consider the difference between relatively small
molecules claimed in pharmaceutical inventions on the one hand, and
large molecules claimed in biotechnological inventions on the other.
Small-molecule chemicals, such as those used in pharmaceutical
applications, have precisely defined structures, usually included in
claims as a chemical drawing or a name that follows the rules of
systematic nomenclature, as seen above with cefdinir.114 Chemical
drawings or names, in themselves, contain a wealth of information
about the molecule, including its precise atomic composition,
111. See Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 336 U.S. 271, 277 (1949).
112. See, e.g., Auto. Techs. Int'l, Inc. v. BMW of N. Am., Inc., 501 F.3d 1274 (Fed. Cir.
2007).
113. See supra note 103 and accompanying text.
114. Of course, chemical patents often claim genera of molecules rather than
individual molecules. For simplicity and ease of comparison, I will initially consider the
case where a claim is directed only to a single molecule.
7 - KARSHIEDT 11.19 (Do NOi DELETE) 11/20/2010 2:29 PM
WINTER 2011] HARD-TO-REPRODUCE INVENTIONS 131
molecular weight, and connectivity of atoms that can be ascertained
by various techniques. Given this structural precision, the identity of
molecules produced in two different laboratories can be confirmed
using established analytical methods such as nuclear magnetic
resonance spectroscopy, mass spectrometry, and elemental analysis."
If the disclosure provides data that tends to establish the structure
and composition of the claimed molecule, or if the data can be
obtained and interpreted in a routine manner by those skilled in the
chemical arts, follow-on researchers can readily confirm the
reproducibility and operability of the claimed invention. At the very
least, armed with the depicted chemical structure or a systematic
chemical name, along with the data for verifying the structure, follow-
on researchers can check if the chemical patent complies with the
§ 101 requirement of operable utility-that is, if the invention actually
works."'
Verifiability of chemical structures, however, has legal
implications beyond simply allowing follow-on researchers to confirm
that the invention is operable. Recall that § 112 requires not only that
the patentee teach how to make the claimed invention, but also how
to use it.1 17 Therefore, enablement of the "full scope of the claimed
invention" necessarily constitutes enablement of "how to use" the
invention across the full scope of the claim for at least one utility
asserted in the patent."' In order for a claim to comply with the "how
to use" prong of the enablement requirement, the specification must
teach those of ordinary skill in the art how to select useful and
operable embodiments of the claim without undue experimentation."
One way to understand a claim to "molecule X" is to view it as
an infinite genus comprising the species "molecule X obtained by
process A," "molecule X obtained by process B," "molecule X
115. See generally DANIEL C. HARRIS, QUANTITATIVE CHEMICAL ANALYSIS (5th ed.
1998); ROBERT M. SILVERSTEIN, FRANCIS X. WEBSTER & DAVID KIEMLE,
SPECTROMETRIC IDENTIFICATION OF ORGANIC COMPOUNDS (7th ed. 2005).
116. See In re Swartz, 232 F.3d 862 (Fed. Cir. 2000).
117. 35 U.S.C. § 112 T 1 (2008) ("The specification shall contain a written description
of the invention, and of the manner and process of making and using it, in such full, clear,
concise, and exact terms as to enable any person skilled in the art to which it pertains, or
with which it is most nearly connected, to make and use the same . . .") (emphasis added).
118. For a recent rejection for lack of how-to- use enablement, see Ex Parte Samuelson,
No. 2008-5927 (B.P.A.I. Feb. 10, 2009) (affirming examiner's rejection of U.S. Pat. App.
No. 10/958,452).
119. See MPEP § 2164.01(c); see also MPEP § 2164.08(b).
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produced by process C," and so on.12 Generally, a composition claim
to a chemical compound is granted even if only one process for
making it is described in the specification.121 While patent law can
often be suspicious of claims to a genus when only one species is
disclosed,12 courts and the USPTO do not raise the issue of
"enablement of the full genus of processes" for composition claims
directed to chemical compounds that are structurally well-defined.
Claims of the type "molecule X" usually do not face such challenges
because the genus "molecule X obtained by process A, B, C, etc." is
not so "diverse and complicated"123 as to lead an examiner to doubt
whether one of ordinary skill in the art can "practice the invention
across the entire scope of the claim." 124 Given the advanced state of
analytical techniques for confirming structures of molecules, follow-
on researchers need possess only ordinary skill to verify that molecule
X that they obtained by process B is the same as the claimed
"molecule X" that was produced by process A disclosed in the
patent's specification. Having confirmed the identity of the molecule,
follow-on researchers can be reasonably confident that a copy of the
patented molecule, even if made by a process different from that
described in the original disclosure, will have the same utilities as
those asserted in the original patent.1' In this way, disclosure of the
structure of molecule X, along with a recitation of its utility, helps
teach follow-on researchers how to use the claimed invention across
the infinite genus of possible processes that produce molecule X.16
120. See Lefstin, supra note 22, at 1168-81 (showing that all claims have infinite scope).
121. MPEP § 2164.01(b).
122. See MPEP § 2164.03.
123. MPEP § 2164.06(b) (discussing the case of In re Wright, 999 F.2d 1557 (Fed. Cir.
1993)).
124. SCHECHTER & THOMAS, supra note 59, at 186.
125. This identity of utilities is exactly what gives generics manufacturers the assurance
that the pursuit of making copies of brand-name pharmaceuticals will yield effective
products. Of course, the FDA's requirements for approval of generics require a great deal
more from generics manufacturers than simply the proof of structural equivalence to the
brand-name product. See U.S. FOOD AND DRUG ADMINISTRATION, Facts and Myths
About Generic Drugs, http://www.fda.gov/Drugs/ResourcesForYou/Consumers/
BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucml67991.htm (last updated
Oct. 13, 2009).
126. The fact that a small molecule will generally behave the same way no matter what
the process of production is goes to one of the Wands factors in the "undue
experimentation" inquiry, namely the predictability or unpredictability of the invention.
See supra note 14. That is, molecule X made by process A will have predictably similar
utility (and likely the same utility) as molecule X made by process B. A claim to an
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The expected identity of utilities of identical chemical compounds,
regardless of the process by which they were made, has the salutary
effect of spurring after-arising technologies involving improved
methods for making desired molecules.1' Knowing, for example, that
a patented compound that is made in limited amounts by extraction
from an exotic plant source is expected to have the same utilities as a
structurally identical compound that is synthesized in the
laboratory, 128 researchers who read the patent claiming the compound
will be encouraged to prepare it on a large scale by a fully synthetic
method.129
B. Issues with Enablement of Biotechnological Inventions
The enablement landscape is quite different for biotechnological
products that function as drugs, such as proteins made by
recombinant deoxyribonucleic acid (DNA) techniques.o3  Before
addressing the differences between biosynthetic proteins and small-
molecule pharmaceuticals, however, it is worth noting the similarities.
infinite genus of processes for making molecule X, therefore, easily satisfies the Wands
predictability factor.
127. For excellent analyses of the correspondence between the enablement
requirement and after-arising technologies, see Kevin Emerson Collins, Enabling After-
Arising Technologies, 34 J. CORP. L. 1083 (2009); Kevin Emerson Collins, The Reach of
Literal Claim Scope into After-Arising Technology: On Thing Construction and the
Meaning of Meaning, 41 CONN. L. REV. 493 (2008).
128. While structural similarity of chemical compounds does not guarantee the same
function or utility, see In re Dillon, 919 F.2d 688 (Fed. Cir. 1990), structural identity
generally does, as long as the follow-on product does not have impurities that interfere
with its functioning; see also supra note 125. See generally John R. Thomas, CONG.
RESEARCH SERV., RL 33605, Authorized Generic Pharmaceuticals: Effects on Innovation
1 (2008).
129. For an interesting example of a composition patent on a natural product, which
was later prepared by synthetic routes, see U.S. Patent No. 5,840,750 (issued Nov. 24,
1998) (disclosing discodermolide, a powerful antitumor agent extracted from a marine
sponge). For examples of methods for making this compound in the laboratory, see Jennie
B. Nerenberg et al., Total Synthesis of the Immunosuppressive Agent (-)-Discodermolide,
115 J. AM. CHEMICAL SOC'Y. 12621 (1993) and Amos Smith III et al., Total Synthesis of
(-)-Discodermolide, 117 J. AM. CHEMICAL SOC'Y. 12011 (1995). By all accounts, research
into making the discodermolide target led to spectacular advances in synthetic organic
chemistry. See Michael Freemantle, Scaled-up Synthesis of Discodermolide, 82 CHEMICAL
& ENGINEERING NEWS 33, 33 (2004) (quoting Steven V. Ley, Professor of Chemistry at
the University of Cambridge, England, as saying that "[t]he ability to make something at
this level of complexity as opposed to extracting it from natural product sources illustrates
the power of modern synthetic chemistry.").
130. JEREMY M. BERG ET AL., BIOCHEMISTRY 157-59, 813-35 (5th ed. 2002)
(presenting an overview of recombinant DNA technique and an overview of protein
synthesis that occurs in the recombinant DNA technique).
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In a landmark 1991 case dealing with biotechnology patents, the
Federal Circuit correctly noted that "a gene is a chemical compound,
albeit a complex one" in the context of determining when an
invention was conceived for the purpose of determining priority."1
This statement also applies to proteins, which are very large and
complex chemical compounds. The critical differences between
pharmaceuticals and proteins, relevant for evaluating enablement of
claims to the two types of chemical compounds, relate to the state of
the art for characterizing and verifying structures of the latter.
First, as already noted, proteins are generally much larger than
organic molecules that serve as active ingredients of pharmaceutical
drugs.13' For example, paroxetine, a well-known small-molecule
pharmaceutical drug marketed under the brand name Paxil@, has the
molecular weight of 329.4 grams per mole in its free-base form,'
while growth hormone, a protein and a biological drug, has the
molecular weight of approximately 22,000 grams per mole in one of
its forms.1 4 What this means in practice is that the latter has many
more atoms than the former, which leads to uncertainties about the
connectivity of the atoms and the three-dimensional structure of the
protein. Large size and complexity of proteins makes it difficult for
pioneering inventors, as well as for follow-on researchers who may
pursue a different process for making the material, to to characterize
its structure given the current state of analytical tools available for
131. Amgen, Inc. v. Chugai Pharm. Co., Ltd., 927 F.2d 1200, 1206 (Fed. Cir. 1991), cert.
denied, 502 U.S. 856 (1991).
132. See Bryan A. Liang, Regulating Follow-on Biologics, 44 HARV. J. ON LEGIs. 363,
369 ("[B]iologics and chemical medicines are tremendously different in size. A biologic
with thousands to millions of atoms forming a highly interconnected group of hundreds to
thousands of amino acids aggregated into chains and subgroups, is much larger than a
chemical drug, which typically consists of just dozens of atoms forming a single
molecule.").
133. Rx List Webpage, The Internet Drug Index, http://www.rxlist.com/paxil-drug.htm
(last visited Nov. 28, 2009).
134. Hans H. Stuting & Ira S. Krull, Determination of Pituitary and Recombinant
Human Growth Hormone Molecular Weights by Modern High-Performance Liquid
Chromatography with Low Angle Laser Light Scattering Detection, 539 J.
CHROMATOGRAPHY A 91 (1991); see also George E. Chapman et al., The 20,000
Molecular Weight Variant of Human Growth Hormone: Preparation and Some Physical
and Chemical Properties, 256 J. BIOLOGICAL CHEMISTRY 2395 (1981). As seen from
these references, even the very determination of approximate molecular weight of human
growth hormone was the product of intensive research efforts, while the molecular weight
of paroxetine can be readily calculated from the atomic weights of constituent atoms
because its precise structure is known.
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protein analysis. Second, and perhaps more important, is the fact
that recombinant proteins are, by definition, made using the
machinery of living organisms. Cell lines from sources such as
bacteria or mammalian organs are engineered (by a process called
transfection, which entails introduction of recombinant DNA that
"codes" for the desired protein into the cell) to synthesize the desired
protein." Because each cell line is unique, the structure and behavior
of the final protein product is highly dependent on the specific cell
line used to synthesize it.m3 Size and complexity of proteins and the
unpredictable nature of their cell-mediated production implicate the
problems of verifiability and reproducibility discussed in the
Introduction."' An article on regulation of the drugs of
biotechnology aptly describes these problems:
Because of the differences in production and size between
biologics and chemical drugs, as well as the unique cellular
source of biologics, it is nearly impossible to make truly
identical copies of a protein using two different production cell
lines.... This diversity is present to an even greater degree
between cell lines from different living organisms, such as
bacteria, mammalian organs, yeast, and other sources.... The
complexity of the biologic molecule, its sensitivity to
production, and the challenges associated with characterization
result in its being defined primarily in terms of its
manufacturing method.
This state of affairs presents two significant problems for follow-
on researchers who wish to take advantage of the teachings of a
patent that includes a broad composition claim to a recombinant
protein (i.e., a protein made using recombinant DNA). First, because
currently available analytical techniques may not always allow one to
determine structures of large proteins with precision, follow-on
researchers sometimes cannot verify, even after extensive
experimentation, if they have reproduced the experiment and made
135. See Liang, supra note 132, at 369-71.
136. See BERG ET AL., supra note 130, for a detailed description of the transfection
method.
137. See Liang, supra note 132, at 370-71.
138. See supra notes 1-11 and accompanying text. In contrast, small-molecule
pharmaceuticals are made by laboratory techniques that tend to be more readily
reproducible, and it is more straightforward to verify their structures.
139. Liang, supra note 132, at 370-71.
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the patented composition.14") Second, because of the high degree of
process dependence in the cell-mediated synthesis of biologics, it is
quite possible that an attempt to make the patented protein by a
different method will yield a product that lacks the asserted utility of
the claimed invention.141
Difficulties in reproducing biological processes, such as cell-
mediated syntheses of large proteins, largely explain why it has taken
a long time to for Congress to pass biosimilars legislation. 142 Indeed,
the contours of the Pathway for Biosimilars Act that was recently
signed into lawl43 are very different from those of the legal regime for
the approval of generics of small-molecule drugs, given the need to
monitor immunogenic response and efficacy of follow-on products
after they are introduced in the marketplace.144  Because of the
limitations of analytical techniques in determining protein structure
and the unpredictability of behavior of biosynthetic products, the
FDA cannot be sure that follow-on biologic drugs will have the same
clinical properties and safety profiles as the branded, patented
products. "[A]s of today, the FDA has not determined how
interchangeability can be established for complex proteins. Different
large protein products, with similar molecular compositions may
140. Even as techniques for determining the primary structure of proteins (i.e.,
connectivity of atoms in a protein) mature, challenges persist for the analysis of secondary
(interaction between fragments of the protein molecule), tertiary (three-dimensional form
of the protein molecule), and quaternary (interaction between the protein molecules)
structure, which can be affected by subtle chemical changes. See Yang Zhang, Progress
and Challenges in Protein Structure Prediction, 18 CURRENT OPINION ON STRUCTURAL
BIOLOGY 342 (2008); see also Liang, supra note 132, at 369 (citing BERG ET AL., supra
note 130, at 51-63); supra note 22 and accompanying text.
141. For example, biological drugs often present the problem of immunogenicity,
whereby the immune system reacts adversely to the drug, sometimes with fatal
consequences. Immunogenicity can severely limit the usefulness of biologic drugs,
particularly in the context of attempts to make follow-on analogs. See Liang, supra note
132, at 375-78.
142. The relationship between biosimilars and branded biological drugs is analogous
to, but not the same as, the relationship between generics and branded pharmaceutical
drugs. See generally Liang, supra note 132.
143. 42 U.S.C § 262 (West 2010); see also William J. Simmons, Biosimilars Pathway: A
Far Cry from Hatch-Waxman, LAW360 (Mar. 30, 2010), http://law360.com/articles/157960.
144. For such provisions in the European biosimilars regulation, see EMEA Guideline
on Similar Biological Medicinal Products Containing Biotechnology- Derived Proteins as
Active Substance: Quality Issues, available at http://www.emea.europa.eu/pdfs/human/
biosimilar/4934805en.pdf (last visited Dec. 28, 2009) and EMEA Guideline on Similar
biological Medicinal Products Containing Biotechnology- Derived Proteins as Active
Substance: Non-Clinical and Clinical Issues, available at http://www.emea.europa.eu/pdfs/
human/biosimilar/4283205en.pdf (last visited Dec. 28, 2009).
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behave differently in people and substitution of one for another may
result in serious health outcomes." 145
Of course, standards of compliance with FDA regulations are not
coextensive with the patent law's enablement requirement. 146  Yet
process-related differences in the behavior of biotechnological
inventions motivate further investigation into whether specifications
can adequately support broad protein composition claims across the
full scope of processes for making the claimed subject matter. In
particular, given the potential differences in utilities of protein
products made by different processes, it is worth analyzing under
what circumstances such claims can satisfy the "how to use" prong of
the enablement requirement.4
C. Toward Process Limitations in Biotechnological Inventions
Difficulties in determining precise structures of proteins, as
detailed above in Part II.B, provide the initial motivation for
proposing that process limitations are appropriate in claims to protein
compositions. As the Sandoz court noted, "if an inventor invents a
product whose structure is either not fully known or too complex to
analyze . . . this court clarifies that the inventor is absolutely free to
use process steps to define this product."14'8 Furthermore, to support
generic claims in arts that are considered unpredictable, such as
chemistry and biochemistry, patent law generally requires a
description of more than one working species of the genus. 149 As the
MPEP puts it, "in applications directed to inventions in arts where the
results are unpredictable, the disclosure of a single species usually
does not provide an adequate basis to support generic claims. .. . [In
unpredictable arts], it is not obvious from the disclosure of one
species, what other species will work."5o
145. Liang, supra note 132, at 372-73 (quoting Press Release, FDA, U.S. FDA
Considerations: Discussion by National Regulatory Authorities with World Health
Organization (WHO) on Possible International Non-Proprietary Name (INN) Policies for
Biosimilars (Sept. 1, 2006)).
146. MPEP § 2164.05 ("[C]onsiderations made by the FDA for approving clinical trials
are different from those made by the USPTO in determining whether a claim is enabled.")
(citing Scott v. Finney, 34 F.3d 1058, 1063 (Fed. Cir. 1994) ("Testing for full safety and
effectiveness of a prosthetic device is more properly left to the [FDA].")).
147. See supra notes 117-119 and accompanying text.
148. Sandoz, 566 F.3d at 1294.
149. See MPEP § 2164.03.
150. Id. (citations omitted); see also Bilstad v. Wakapoulos, 386 F.3d 1116, 1125 (Fed.
Cir. 2004) ("If the difference between members of the group is such that the person skilled
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This principle is related to the holding of the venerable
Incandescent Lamp Patent case, where a patent was held invalid
because disclosed species of materials for use as light bulb filaments
did not support the claimed genus of "carbonized fibrous or textile
material."' The claim was not enabled because many species within
the genus were not useful as filaments, and the claimed genus as a
whole did not seem to have a unifying property that allowed species
within it to be useful for their asserted purpose. 2  Stated another
way, the disclosed species, even though they were members of the
genus "carbonized fibrous or textile material," could not support the
inductive step of concluding that other members of the genus would
have the desired utility.1 3 This failing was illustrated by the struggles
of one follow-on researcher, Thomas Edison, to get other members of
the claimed genus to work as filaments for incandescent light bulbs.' 4
in the art would not readily discern that other members of the genus would perform
similarly to the disclosed members, i.e., if the art is unpredictable, then disclosure of more
species is necessary to adequately show possession of the entire genus."). Note, however,
that Bilstad approached the problem of overclaiming through the written description,
rather than enablement, analysis.
151. Consol. Electric Light Co. v. McKeesport Light Co., 159 U.S. 465, 468 (1895).
152. Id. at 472. ("[The patentees] made a broad claim for every fibrous or textile
material, when in fact an examination of over six thousand vegetable growths showed that
none of them possessed the peculiar qualities that fitted them for that purpose. Was
everybody then precluded by this broad claim from making further investigation? We
think not."). The Court further noted:
[T]o hold that one who had discovered that a certain fibrous or textile material answered
the required purpose should obtain the right to exclude everybody from the whole domain
of fibrous and textile materials, and thereby shut out any further efforts to discover a
better specimen of that class than the patentee had employed, would be an unwarranted
extension of his monopoly, and operate rather to discourage than to promote invention.
Id. at 476.
153. One author described this problem as the patentee's assertion of a "false
inventive genus." Brian P. O'Shaughnessy, The False Inventive Genus: Developing a New
Approach for Analyzing the Sufficiency of Disclosure Within the Unpredictable Arts, 7
FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 147 (1996).
154. Consol. Electric Light Co., 159 U.S. at 472-73 ("The injustice of [upholding the
validity of the 'carbonized fibrous or textile material' genus] is manifest in view of the
experiments made, and continued for several months, by Mr. Edison and his assistants,
among the different species of vegetable growth, for the purpose of ascertaining the one
best adapted to an incandescent conductor. Of these he found suitable for his purpose
only about three species of bamboo, one species of cane from the valley of the Amazon ...
and one or two species of fibers from the agave family."). The art of making incandescent
light bulbs was certainly an unpredictable one in the nineteenth century!
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In modern terms, Edison could not select operative embodiments of
the disputed claim without undue experimentation.
Similar to the molecular chemistry example discussed above in
Part II.A, the relevant "process" genus of biosynthetic proteins is
"Protein X obtained by process A, B, C, etc." Since biotechnological
inventions are unpredictable in the sense that a different process that
appears to produce the claimed product actually may not yield a
material of the same utility as the claimed material,15 it is not clear
that a specification that discloses a single process for making Protein
X enables those skilled in the art to practice and use the claimed
invention across the full range of possible processes for making
Protein X. Of course, it is settled law that a patent cannot be held
invalid for lack of enablement of after-arising technology, because
enablement is measured at the time of the filing and one cannot
enable something that is not yet known.'5 But if several processes for
preparing materials that fall within the claimed composition are
known at the time of the filing, it is reasonable that the applicant be
required to disclose more than one process for producing the claimed
product that exhibits the utilities asserted in the specification, given
that proteins synthesized by different methods can have
unpredictably different properties. If the applicant does not or
cannot make the requisite showing, the composition claim to the
protein product should include a process limitation or else risk
rejection or an invalidity judgment for lack of enablement.
155. See J. Benjamin Bai, Enablement Issues Concerning Aggressively Broad Generic
Claims, 7 Nw J. TECH. & INTELL. PROP. 1, 3-13 (2008) (putting the Incandescent Lamp
Patent case in the context of modern enablement law).
156. See supra notes 135-145. Utility concerns over broad composition claims have
motivated courts to invalidate claims for lack of enablement. For example, the Federal
Circuit in Amgen, Inc. v. Chugai Pharm. Co., Ltd., 927 F.2d 1200 (Fed. Cir. 1991), cert.
denied, 502 U.S. 856 (1991), held a biotechnology claim invalid because of "attendant
uncertainty as to what utility will be possessed by these [claimed but untested] analogs."
Id. at 1214; cf MPEP § 2164.08(b) (noting that claims can be rejected for lack of
enablement if they read on a "significant numbers of inoperative embodiments ... when
the specification does not clearly identify the operative embodiments and undue
experimentation is involved in determining those that are operative.").
157. See In re Hogan, 559 F.2d 595 (C.C.P.A. 1977). Nevertheless, a recent Federal
Circuit decision made it clear that the enablement inquiry is no less lenient for
"pioneering" patents than for "routine" patents. See Plant Genetic Sys., N.V. v. DeKalb
Genetics Corp., 315 F.3d 1335 (Fed. Cir. 2003).
158. Of course, the former remedy (introduction of a process limitation) would occur
at the patent prosecution stage, while the latter remedy (invalidation) would occur at the
litigation stage.
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D. The Amgen v. Hoechst Case
One of the patents"'9 at issue in the well-known case of Amgen
Inc. v. Hoechst Marion Roussel, Inc."" illustrates how a composition
claim to a protein may not be fully enabled across the range of
possible preparative processes. For example, one of the independent
claims of the patent reads as follows:
"3. A non-naturally occurring erythropoietin glycoprotein having
the in vivo biological activity of causing bone marrow cells to increase
production of reticulocytes and red blood cells, wherein said
erythropoietin glycoprotein comprises the mature erythropoietin
amino acid sequence of Fig. 6.""'
At first glance, the structure of the claimed protein,
erythropoietin (EPO), appears to be defined precisely, which suggests
that we should treat it no differently than claims to small molecules
where, as we saw, no process limitations are warranted. After all,
proteins consist of building blocks called amino acids, so the sequence
of amino acids (as listed in Figure 6 of the '080 patent), which gives
both the identity and the order of these building blocks, provides a
precise and verifiable structural description of the molecule.6 2 This
characterization is misleading, however. The claimed protein is a
"glycoprotein," which means that some of the amino acid building
blocks of the protein have various oligosaccharide moieties (i.e.,
sugar, or carbohydrate, molecule fragments) attached to them."'
Therefore, Claim 3 really reads on a large number of compositions
that include the claimed amino acid sequence decorated with varying
numbers, types, and locations of sugar substituents, collectively
described as "glycosylation."164 A protein's glycosylation is extremely
difficult to control in the course of its cell-mediated production, but it
can make all the difference in the clinical and diagnostic utilities of
the protein, which are the utilities asserted in the '080 patent."'
159. U.S. Patent No. 5,621,080 (issued Apr. 15, 1997) ("the '080 patent").
160. 314 F.3d 1313 (Fed. Cir. 2003).
161. Id., col. 38, 1. 45-50.
162. BERG ET AL., supra note 130, at 813-35.
163. Anne Dell & Howard R. Morris, Glycoprotein Structure Determination by Mass
Spectrometry, 291 SCIENCE 2351 (2001).
164. Id.
165. '080 patent, col. 9, 1. 16-21 ("it is consequently projected in the art that the best
prospects for fully characterizing mammalian erythropoietin and providing large
quantities of it for potential diagnostic and clinical use involve successful application of
recombinant procedures to effect large scale microbial synthesis of the compound.")
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Furthermore, it is very difficult to determine the location of
sugar substituents in a glycoprotein."' While techniques for analyzing
glycosylation are improving, the best one could do at the time the
application for the '080 patent was filed was to figure out the
aggregate amount of the various types of oligosaccharides attached to
the protein, but not necessarily their locations. Difficulties with
reproducibility and verifiability have made this area of science
extremely challenging; high degree of process dependence in
glycoprotein synthesis is one of the reasons why a follow-on biological
drug manufacturer cannot use the regulatory route available to
generic drug manufactures to get its product approved by the FDA.,,
Because structure and bioactivity of EPO is highly-process
dependent, it is worth inquiring further whether how-to-use
enablement of Claim 3 of the '080 patent necessitates demonstration
of the asserted utility (or utilities) of claimed EPO made with more
than one process known at the time of the filing.6
Before the enablement issue is addressed, however, the rest of
Claim 3 deserves mention. This claim includes two limitations other
than the amino acid sequence (which, as we saw above, only begins to
tell the structural story of EPO): the preambular phrase "non-
(emphasis added). For general background on glycosylation, see KURT DRICKAMER &
MAUREEN E. TAYLOR, INTRODUCTION To GLYCOBIOLOGY (2nd ed. 2006).
166. Determining glycosylation was an important barrier in the development of
proposed regulatory regimes for the approval quasi-generic versions of biologic drugs.
See, e.g., Access to Life-Saving Medicine Act, H.R. 1038, 110th Cong. § 3(a)(2)(k)(1)(A)-
(H) (2007) (noting that characteristics for evaluating biosimilars include: "data on
comparability, comparability of principal molecular structure, posttranslational events,
infidelity of translation or transcription, amino acid sequence, polysaccharide repeating
units, glycosylated protein product structure") (emphasis added); see also notes 135-145
and accompanying text.
167. '080 patent, col. 32, 1. 66 - col. 33, 1. 3 ("Preliminary analyses reveal significant
heterogeneity in products produced by the expression system, likely to be due to
variations in glycosylation of proteins expressed, and relatively high mannose content of
the associated carbohydrate.").
168. See David M. Dudzinski, Reflections on Historical, Scientific, and Legal Issues
Relevant to Designing Approval Pathways for Generic Versions of Recombinant Protein-
Based Therapeutics and Monoclonal Antibodies, 60 FOOD & DRUG L.J. 143, 224 (2005).
The relevance of the lack of FDA approval is that it provides evidence of possible lack of
utility due to process dependence in glycoprotein biosynthesis. See supra note 146 and
accompanying text.
169. This is so because it would require undue experimentation for a person of
ordinary skill in the art to select the process for making EPO with the asserted utilities.
See supra notes 117-129 and accompanying text; see also infra notes 182-193 and
accompanying text.
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naturally occurring" and the functional "biological activity" element.
In evaluating the accused infringer's § 112 invalidity challenge to
Claim 3, the court refused to read "non-naturally occurring" as any
kind of a process or source limitation, saying simply that the
recitation of "non-naturally occurring" helped the claim meet the
§ 101 subject matter eligibility requirements (since naturally occurring
EPO would not be patentable subject matter unless it was isolated
from a natural source and purified).
But one wonders if the phrase "non-naturally occurring" should
have had more teeth as a limitation. "Non-naturally occurring"
implies a laboratory synthesis rather than isolation from a natural
source; in the '080 patent, that laboratory synthesis involved
transfection of host cells with exogenous, or "foreign" DNA, which
the specification portrays as "uniquely characteriz[ing]" the
invention.1  In reviewing the district court's claim construction, the
Federal Circuit did not make much of the "uniquely characterized"
phrase, saying only that the plain language of the claim did not limit it
to the transfection method.1  In his dissent, Judge Clevenger made
perhaps too much of that phrase; he argued that transfection by
exogenous DNA is a "necessary element" of the claimed invention
and its absence from the independent claims should have led to a
holding of invalidity for lack of enablement.174 Lack of enablement
for failure to recite a necessary claim element is a rarely invoked
doctrine, which appears to be used only when the patentee
unequivocally says in the specification that the patent will not work
without it.
170. Amgen Inc. v. Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1329 (Fed. Cir. 2003).
("By limiting its claims in this way Amgen simply avoids claiming specific subject matter
that would be unpatentable under § 101."). See also infra note 232 and accompanying text.
171. See supra note 136.
172. '080 patent, col. 10, 1. 24.
173. Amgen, 314 F.3d at 1326 (noting, in the context of a patent with claims similar to
that of the '080 patent, that "[t]he plain meaning of the claims controls here, and they
plainly are not so limited"). It is unclear that this analysis would survive the holding of
Phillips v. AWH Corp., 415 F.3d 1303, 1315-17 (Fed. Cir. 2005) (en banc) (emphasizing
the importance of the specification for ascertaining the meaning of claim terms).
174. Amgen, 314 F.3d at 1360 (Clevenger, J., dissenting in part).
175. In re Mayhew, 527 F.2d 1229, 1232-33 (C.C.P.A. 1976); MPEP § 2172.01; cf
Gentry Gallery, Inc. v. Berkline Corp., 134 F.3d 1473, 1479-80 (Fed. Cir. 1998) (proposing
what appears to be an "essential element" test to evaluate whether claims met the written
description requirement); MPEP § 2164.08(c).
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Judge Clevenger's second argument, directed to another patent
at issue in the case and based on the rationale of In re Vaeck,17 more
closely addresses the enablement problem of Claim 3 of the '080
patent. In Vaeck, the patentees claimed, in relevant part, a "chimeric
gene capable of being expressed in Cyanobacteria cells,"'77 but the
working examples in the specification taught only a single strain of
cyanobacteria where the claimed expression took place.17 ' The court,
speaking through Judge Rich, held that "there is no reasonable
correlation between the narrow disclosure in appellants' specification
and the broad scope of protection sought in the claims encompassing
gene expression in any and all cyanobacteria. "79 The court made
much of the fact that cyanobacteria are in fact divided into multiple
genera, are a "diverse and poorly understood group of
microorganisms," and are generally unpredictable in their gene
expression behavior given how little is known about them.1o
Therefore, disclosure of only one species of cyanobacteria, and a
mere mention of a few other species and genera of the organism, did
not entitle the patentees to claiming genes expressed in the whole
universe of cyanobacteria."'
Analogously, Claim 3 of the '080 patent implicitly claims the
genus of all possible methods for making "non-naturally occurring
EPO," limited only by its amino acid sequence and the biological
function of "causing bone marrow cells to increase production of
reticulocytes and red blood cells." At the time of the filing, several
methods for making "non-naturally occurring" EPO were available,
including the transfection method that the patentee perfected and the
chemical synthesis method mentioned repeatedly in the specification
of the '080 patent.182 In actuality, the patentee disclosed only chemical
syntheses of fragments of the full amino acid sequence of the EPO
176. In re Vaeck, 947 F.2d 488 (Fed. Cir. 1991).
177. Id. at 490.
178. Id.
179. Id. at 495.
180. Id. at 496. The court further held that [t]here must be sufficient disclosure ... to
teach those of ordinary skill how to make and how to use the invention as broadly as it is
claimed," and that, for such an unpredictable art, "the required level of disclosure will be
greater than, for example, the disclosure of an invention involving a 'predictable' factor
such as a mechanical or electrical element." Id.
181. Id.
182. See, e.g., Abstract of the '080 patent ("Disclosed also are chemically synthesized
polypeptides disclosing the biochemical and immunological properties of EPO.").
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(which exhibit no asserted biological activity) rather than the entire
sequence."3 The patentee, therefore, really taught only one "species"
of at least two possible processes for making EPO, the transfection
184process.
Although his argument for non-enablement of the '080 patent
was primarily based on the theory that the claims at issue did not
recite an essential element, Judge Clevenger indicated his general
discomfort with the disclosure of only one method to support a broad
composition claim in a related patent at the outset of his Amgen
dissent: he was skeptical of whether "one means of producing
synthetic EPO, namely exogenous DNA expression [or transfection]
entitles [the patentee] to claim all EPO produced by mammalian cells
in culture.""' Similarly, disclosure of one method for producing
"non-naturally occurring EPO" should not have entitled the patentee
to broadly claim, as he did in the '080 patent, the amino acid sequence
with the various possible glycosylation patterns and corresponding
differences in utility and performance that variations in glycosylation
can cause. Crucially, this position is strengthened by the realization,
likely true now and certainly true at the time of the filing of the '080
patent, that the art of protein synthesis was (and is) highly
unpredictable and the correspondence in structure between EPOs
made by transfection (as disclosed in the '080 patent) and those made
by other methods (like those made by the accused infringer in the
Amgen case, for example)"' is very difficult to show. Indeed, due to
183. '080 patent, col. 35,1. 4-21.
184. The specification of the '080 patent suggests that yet another process for making
claimed EPO, affinity purification, was known at the time of the filing: "While polyclonal
and monoclonal antibodies as described above provide highly useful materials for use in
immunoassays for detection and quantification of erythropoietin and can be useful in the
affinity purification of erythropoietin, it appears unlikely that these materials can readily
provide for the large scale isolation of quantities of erythropoietin from mammalian
sources sufficient for further analysis . . . ." ('O80 patent, col. 9, 1. 7-12).
185. Amgen Inc. v. Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1359 (Fed. Cir. 2003)
(Clevenger, J., dissenting in part). Note that the shortcoming of Claim 3 is strikingly
similar to that of the claims at issue in Auto. Techs. Int'l, Inc. v. BMW of N. Am., Inc., 501
F.3d 1274 (Fed. Cir. 2007), which dealt with the patent where the plaintiff claimed a
method that encompassed both mechanical and electronic sensors but said very little
about electronic sensors in the specification. The patent was held invalid due to lack of
enablement across the full scope of the claimed invention. The court made much of the
fact that the electronic sensors, which represented a "distinctly different" embodiment of
the invention, were not enabled. Id. at 1285; see also Liebel-Flarsheim Co. v. Medrad,
Inc., 481 F.3d 1371 (Fed. Cir. 2007) (invalidating claims for lack of enablement on similar
grounds).
186. Amgen, 314 F.3d at 1325.
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the unpredictability of the field and the limitations of the synthetic
and analytical arts, a person skilled in the art would understand that
different methods for synthesizing EPOs that fall within Claim 3 of
the '080 patent may not yield clinically and diagnostically useful
materials without undue experimentation (though they may
technically "cause bone marrow cells to increase the production of
reticulocytes or red blood cells," as the claim requires). The district
court did not grapple with this issue: "[B]ecause the asserted claims
were to 'compositions' rather than 'processes,' 'the specification need
teach only one mode of making and using a claimed composition.'
The appellate panel also thought that one method was enough:
"Amgen also described and enabled at least one method of producing
EPO that was . . . 'non-naturally occurring' . . .: the genetic
manipulation of CHO and COS-1 cells." 9
The district court and the Federal Circuit applied traditional
small-molecule law to the biotechnology problem at hand,'o holding
that a description of one method of making the claimed protein is
sufficient to support a broad composition claim to the protein.9
While the district court's statement is certainly correct in regard to
small-molecule chemicals of precisely defined structure, it is less
supportable when applied to large proteins at issue in the Amgen
case. In the biotechnological arts, where the structure of a product
and its utility are intimately connected to the method of its
production, disclosure of one method in support of a broad
composition claim likely does not meet the "reasonable correlation" 19 2
187. See supra notes 163-167. Recall that unpredictability of the art and breadth of the
claims are two of the Wands factors in the inquiry whether experimentation is undue. See
supra note 14; see also supra note 126 and accompanying text.
188. Amgen, 314 F.3d at 1359 (Clevenger, J., dissenting) (quoting Amgen Inc. v.
Hoechst Marion Roussel, Inc., 126 F. Supp. 2d 69, 160 (D. Mass. 2001)).
189. Id. at 1335.
190. See MPEP § 2164.01(b) (noting that "[a]s long as the specification discloses at
least one method for making and using the claimed invention that bears a reasonable
correlation to the entire scope of the claim, then the enablement requirement of 35 U.S.C.
112 is satisfied").
191. See Jeffrey A. Lefstin, The Constitution of Patent Law: The Court of Customs and
Patent Appeals and the Shape of the Federal Circuit's Jurisprudence, 43 LOy. L.A. L. REV.
843, 875 (2010) (defining the question presented in Amgen as whether "the disclosure of
one method of synthesizing a natural product permit the patentee to claim essentially all
synthetic versions of the product").
192. In re Fisher, 427 F.2d 833, 839 (C.C.P.A. 1970).
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and "undue experimentation"" standards of enablement. Indeed,
these standards were not met by Claim 3 of the '080 patent, which
claimed the universe of non-naturally occurring EPOs of unknown
utility, containing an untold number of glycosylation patterns, without
any process limitations. The Federal Circuit should have reversed the
district court and held the claim invalid for lack of enablement under
§ 112 1.
E. Rescuing Claim Validity with Process Limitations
Since the patentee did not have enough information to limit the
structure of EPO in Claim 3 by pinning down locations and types of
glycosyl moieties on the amino acids of the protein, a process
limitation would have been a logical alternative for narrowing the
claim so that it would meet the enablement requirement. Indeed,
such limitations are useful precisely when the structure of the product
is not fully known.194 Perhaps realizing that his disclosure did not
support broad composition claims, the applicant originally drafted
key claims of the application that became the '080 patent with process
limitations. Of course, the applicant then tried for something more,
and the rest is history.'96
193. In re Wands, 858 F.2d 731, 733 (Fed. Cir. 1988).
194. See supra note 148 and accompanying text.
195. Amgen, 314 F.3d at 1329. Claim 1 as originally filed read as follows: "A purified
and isolated polypeptide having part or all of the primary structural conformation and one
or more of the biological properties of naturally occurring erythropoietin and
characterized by being the product of prokaryotic or eukaryotic expression of an exogenous
DNA sequence." U.S. Pat. App. No. 08/468,556, Original Application, at 97 (filed June 6,
1995) (emphasis added to flag the process element).
196. The applicant made a preliminary amendment, cancelling all the originally filed
claims (including the claim reproduced supra in note 195) and adding several new claims.
The filing was preceded by an examiner interview where it was noted that "[a]pplicant
intends to file preliminary amendment.... Exr. [examiner] favorably impressed." U.S.
Pat. App. No. 08/468,556, Examiner Interview Summary Record (Dec. 11, 1996) (Claims A
and B accompanying the interview report became Claims 1 and 2 of the '080 patent).
Interestingly, the claim that was to become Claim 3 of the '080 patent was not discussed
with the examiner but added anyway in the amendment that followed the interview. The
applicant's remarks confirm that "[n]o discussion was had during the interview concerning
the specific subject matter of newly-submitted claim[] 71," which became Claim 3. Third
Preliminary Amendment and Terminal Disclaimer Pursuant to 37 C.F.R. § 1.321, at 9 (filed
Dec. 20, 1996). All of the claims filed as part of this amendment were allowed without any
subsequent substantive amendments or office actions. Claim 3, of course, was the crucial
claim in the '080 patent. The prosecution history can be obtained from the USPTO and is
also on file with the author.
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Interestingly, an Amgen patent from the same family as the '080
patent has a dependent claim with the kind of a process limitation
that would also be appropriate for the '080 patent:
3. A non-naturally occurring glycoprotein product of the
expression in a mammalian host cell of an exogenous DNA
sequence comprising a DNA sequence encoding human
erythropoietin, said product possessing the in vivo biological
property of causing bone marrow cells to increase production of
reticulocytes and red blood cells.19
Note that the claim does not have the traditional process or
source limitation phrasing, such as "obtained by" or "derived from."
The emphasized portion, however, does serve as a pair of process
elements, the first limiting the source of the glycoprotein to "a
mammalian host cell" and the second limiting the triggering of cell
expression (i.e., synthesis) of EPO to "an endogenous DNA
sequence," which captures the transfection process. To be sure, the
glycoprotein described in the claim is not immune to structural
unpredictability arising from process- or source-based variations.
Glycosylation of the claimed material is still dependent on the type of
host cell used to express it, for example. Nevertheless, the two
limitations in this claim make the correlation between disclosure and
scope of the claim reproduced above significantly more reasonable
than that in Claim 3 of the '080 patent. For example, the specification
of the '993 patent (which is the same as that of the '080 patent, as the
two have the same parent application) discloses EPO made by
transfection of at least two types of mammalian host cells: COS-1
(from kidney cells of the African green monkey carrying the SV40
genome) and CHO (from Chinese hamster ovary)."' There is no
guarantee, of course, that EPO that falls within the scope of the
above claim, but is made from host cells other than COS-1 or CHO,
will have the utilities of the EPO disclosed in the examples of the '933
patent. The patentee's demonstration of production of useful EPO in
two widely used cell lines from two different mammalian species,
however, makes a strong case for the enablement of the claim. As for
the "expression . .. of an exogenous DNA sequence" limitation, it is
197. U.S. Patent No. 5,547,933 (issued Aug. 20, 1996) ("the '933 patent") (emphasis
added). See supra note 196 for another example of appropriate process limitation
language.
198. '933 patent, col. 10, 1. 42 and Examples 6-10.
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appropriate, as argued above,"' because the patentee disclosed only
one process for making the structurally unpredictable glycoprotein.2
Thus, taking a cue from the patentee, one may revise Claim 3 of
the '080 patent to say the following:
A non-naturally occurring erythropoietin glycoprotein derived
by an expression of an exogenous DNA sequence in a
mammalian host cell having the in vivo biological activity of
causing bone marrow cells to increase production of
reticulocytes and red blood cells, wherein said erythropoietin
glycoprotein comprises the mature erythropoietin amino acid
sequence of Fig. 6.
This formulation, with the source and process limitations
emphasized, ensures that the claim has a reasonable correlation to the
specification, which principally discloses the transfection method for
producing EPO. Of course, were the patentee able to obtain and
disclose additional structural information on the EPO that he had
made, including locations and types of glycosyl groups on the various
amino acids of the EPO, he would have been free to draft
composition claims with only structural limitations.2 1 The follow-on
researcher, then, could set out to make the claimed structures by the
same or different process and, in the course of doing so, confirm or
disconfirm the operability and utility of the claimed invention. In the
absence of particularized structural information, however, the
patentee would have to show more than one method of making the
claimed composition and confirm the utility of the claimed material
made by the two or more methods in order to obtain a valid
composition claim unencumbered by process limitations.
199. See supra Part IID.
200. Claim 3 of the '933 patent was never asserted in the Amgen litigation, of course,
because the accused infringer did not use the process in the claim, but relied on a
completely different process that involved tricking endogenous DNA into making the host
cell express (i.e., synthesize) the desired EPO. Amgen, 314 F.3d at 1325.
201. Allowing broad composition claims without meaningful structural or process
limitations creates a de facto more lenient standard for biotechnological patents relative to
chemical patents. Accord Natalie A. Lissy, Note, Patentability of Chemical and
Biotechnology Inventions: A Discrepancy in Standards, 81 WASH. U. L.Q. 1069 (2003).
7 - KARSHIED1 11.19 (Do NoT DELETE) 11/20/2010 2:29 PM
WINTER 2011] HARD-TO-REPRODUCE INVENTIONS 149
IV. Required Process Limitations and Their Consequences
A. Enforcement of Process Limitations
The USPTO cannot require patent applicants to draft claims
with specific types of limitations. Patent examiners can, however,
encourage patentees to use such limitations by issuing Office Actions
rejecting certain composition claims without process limitations for
lack of enablement.2 2 A proper analysis by an examiner would first
consider the claim's structural, physical, and other limitations and
determine the level of structural precision at which the product is
described in the claim. The EPO of Claim 3 of the '080 patent, for
example, was described precisely at the level of its amino acid
sequence but not at the level of glycosylation. If the subject matter of
the claim lacks structural precision (such as uncertain positioning of
glycosyl groups in glycoproteins), the examiner may then consider the
claimed product as a genus of processes for making it, if it is known in
the art that process variations can lead to uncertainties in the
structure and utilities of the claimed product. Once the product is
cast as a genus of processes, the examiner would proceed with the
standard enablement inquiry to see if the disclosure supports the full
product genus (i.e., composition claim that is not limited by a
process). How many processes for making the claimed product are
described in the specification? Are the disclosed processes
sufficiently different, such as fully chemical and recombinant methods
for making EPO, as to be representative of the full product genus,
free of process limitations? Do products made by the different
processes have the utilities asserted in the patent? Would undue
experimentation be required to select processes for making useful
embodiments of the product?
If the examiner determines that a composition claim free of
process limitations is not adequately supported by the specification,
he or she should reject the claim as failing to meet the enablement
requirement of § 112 1. The applicant can then amend the claim by
introducing appropriate process, structural, or physical limitations.
For products whose structure cannot be determined precisely, process
limitations may be the only choice for ensuring that the claim meets
the enablement requirement.
202. MPEP § 2260.
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B. Potential Consequences of Enforcing Process Limitations
Clearly, process limitations would reduce the level of protection
available to patentees in the biotechnological arts, but whether or not
such diminished protection would discourage or encourage
innovation is a difficult question. At the very least, commentators
have identified a tradeoff between too much and too little protection;
as Merges and Nelson noted in a classic paper, "every potential
inventor is also a potential infringer . .. [A] 'strengthening' of
property rights will not always increase incentives to invent; it may do
so for some pioneers, but it will also greatly increase an improver's
chances of becoming enmeshed in litigation." 203 What seems clear,
however, is that patentees can retain a meaningful level of protection
with claims that include process limitations.
Consider a recent Federal Circuit case, decided several months
after Sandoz, again dealing with Amgen's biotechnology products.2 4
In Hoffmann-La Roche, one of the claims asserted by Amgen was
Claim 3 of the '933 patent, discussed extensively in Part II.E. The
accused product, called MIRCERA@, was made with "EPO
produced in and purified from mammalian cells,"20" which was further
modified with polyethylene glycol (PEG). The Federal Circuit
affirmed the district court's summary denial of Judgment as a Matter
of Law (JMOL) to Hoffmann-La Roche on the issue of non-
infringement of Claim 3, thereby sustaining a jury verdict of
infringement, because "MIRCERA@ embodies the human EPO and
source limitations of the asserted claims." 206 The "mammalian host
cell" source limitation of Claim 3207 did not weaken the claim to the
point that Amgen could not win an infringement lawsuit. The
researchers of Hoffmann-La Roche, a leading pharmaceutical
203. Robert P. Merges & Richard R. Nelson, On the Complex Economics of Patent
Scope, 90 COLUM. L. REV. 839, 916 (1990). But see Edmund W. Kitsch, Elementary and
Persistent Errors in the Economic Analysis of Intellectual Property, 53 VAND. L. REV.
1727, 1739-40 (2000) (arguing that other commentators have underestimated the
importance of patent licensing, which can help inventors avoid litigation).
204. Amgen Inc. v. F. Hoffmann-La Roche Ltd., 580 F.3d 1340 (Fed. Cir. 2009).
205. Id. at 1376.
206. Id.
207. Source limitations are treated the same way as process limitations by the Federal
Circuit. See supra note 37 and accompanying text.
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company and a competitor of Amgen,2 08 made a product that fell
within the scope of Claim 3 of Amgen's well-known '933 patent on
EPO, source or process limitations notwithstanding.
Claim 3 of the '933 patent and related claims also survived an
invalidity challenge in the same case, based on a prior publication by
Eugene Goldwasser and co-workers,2 9  which disclosed EPO
produced from human urine.21  Hoffmann-La Roche argued that the
"derived ... in a mammalian host cell" limitation was the only
limitation of Claim 3 that was not disclosed by Goldwasser. Because
"a claimed product shown to be present in the prior art cannot be
rendered patentable solely by the addition of source or process
limitation,"21  Hoffmann-La Roche asserted that Goldwasser's urinary
EPO anticipated Claim 3 of the '933 patent.212 The court, however,
pointed to expert testimony in the trial record, which demonstrated
that Amgen's recombinant EPO differed structurally from the urinary
EPO disclosed in the prior art.2 The Federal Circuit agreed with the
district court and Amgen's experts in that "the source limitation
imparts both novel structure and function onto EPO" 214 and upheld
208. Kerry A. Dolan, Diagnosing Amgen, FORBES, Oct. 25, 2006, available at
http://www.forbes.com/2006/10/25/leadership-amgen-pharmaceutical-lead-
managecz-kd_1025amgen.html.
209. Takaji Miyake, Charles K.-H. Kung & Eugene Goldwasser, Purification of
Human Erythropoietin, 252 J. BIOLOGICAL CHEMISTRY 5558 (1977).
210. Amgen Inc. v. F. Hoffmann-La Roche Ltd., 580 F.3d 1340, 1363-70 (Fed. Cir.
2009).
211. Amgen Inc. v. Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1354 n.20 (Fed. Cir.
2003); see also Hoffmann-La Roche, 580 F.3d at 1366 (citing Gen. Elec. Co. v. Wabash
Appliance Corp., 304 U.S. 364, 373 (1938) (noting that "[i]t has long been the case that an
old product is not patentable even if it is made by a new process")); supra notes 64-65 and
accompanying text.
212. Hoffmann-La Roche, 580 F.3d at 1364. In addition to appealing the district
court's denial of JMOL on the issue of invalidity, Hoffmann-La Roche appealed the
district court's denial of a new trial, which it sought based on erroneous jury instructions
that did not mention the special rule that process limitations cannot impart novelty to a
product-by-process claim to an old product. Id. at 1368. The Federal Circuit denied this
appeal as well because the claim was not anticipated, and the jury instructions were
therefore non-prejudicial. Id. at 1369.
213. Id. at 1367 (referring to expert testimony that showed differences in
carbohydrate composition of recombinant EPO and urinary EPO"). The court cited this
evidence in upholding the validity of an EPO claim in another Amgen patent, but the
evidence applies with equal force to Claim 3 of the '933 patent. "For purposes of the
source limitation, which is what is at issue, there essentially is no difference between [the
other claim] ... and claim 3 of the '933 patent ..... Id. at 1369.
214. Id. at 1365.
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the novelty of the disputed claim. This move is worth noting. Even
though the claim at issue lacks a novelty-imparting structural
limitation, external evidence was admitted to show that a process
limitation corresponds to a structural difference between the claimed
material and the prior art, thereby rendering the claimed material
novel. Acknowledgement that the structure and function of a prior
art EPO was difficult to reproduce and verify, so that the change in
the process apparently created a different structure (yet one that was
not and probably could not be captured in a structural limitation),
rescued the validity of the claim from an anticipation challenge.2'
The Hoffmann-La Roche decision shows that process limitations
can be an important tool in the hands of patent applicants. If
potential structural limitations are difficult to pin down or appear to
be overly restrictive, a process limitation can be introduced as a proxy
for a novel structure and help establish the patentability of a claim
over the prior art.2 6 Indeed, the unique status of composition claims
with process limitations, reflected in the fact that such claims are not
subject to the maxim "that which infringes if later anticipates if
earlier,"217 may help make up for the reduced level protection of such
claims relative to "pure" composition claims. As the Federal Circuit
noted in Hoffmann-La Roche, "an accused product may meet each
limitation in a claim, but not possess features imparted by a process
limitation that might distinguish the claimed invention from the prior
art."218
A related issue to consider is whether enforcement of the
enablement requirement through process limitations affects the
analysis of whether prior art is sufficiently enabling as to be
anticipatory.2 9 In analyzing cases on enablement by prior art, the
Federal Circuit noted: "The disclosure in an assertedly anticipating
reference must be adequate to enable possession of the desired
subject matter. It is insufficient to name or describe the desired
subject matter, if it cannot be produced without undue
experimentation." 2() In biotechnological arts, it is likely that prior art
215. Cf supra Part II.E.
216. See also supra Part I.C.
217. Hoffmann La-Roche, 580 F.3d at 1370.
218. Id.
219. See supra notes 23-24 and accompanying text.
220. Elan Pharms., Inc. v. Mayo Found. for Med. Educ. & Research, 346 F.3d 1051,
1055 (Fed. Cir. 2003).
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would almost always have to describe a method of making the
disclosed product and provide adequate identifying data in order to
be enabling, since, as discussed above in Part II.B, structure and
identity of biotechnological products can be highly process-dependent
and difficult to ascertain. 2 1 Furthermore, as Hoffm ann-La Roche
suggests, an applicant can defeat the charge of anticipation by
submitting evidence of structural differences between the claimed
product and the material disclosed in prior art.222 Such an approach
has the salutary effect of rewarding applicants who perform
laboratory experiments rather submit mere paper patent
applications.2 It is important to note, however, that this Article does
not propose heightened enablement or "working prototype"
requirements for biotechnological arts. Rather, the Article argues for
restricting claims to certain process-dependent inventions to ensure
commensurability between claim scope and disclosure that is
understood to be a part of the enablement requirement in patent
aw224law.2
V. Conclusion
The proposal described in this Article is controversial. It is
unquestionable that process limitations would weaken the level of
protection available to patentees who invent in the field of
biotechnology. Nevertheless, the arguments advanced herein are
meant to stay firmly within the confines of the enablement doctrine as
it has been developed from foundational cases such as the
Incandescent Lamp Patent case to modern decisions such as In re
Fisher, In re Wands, and In re Vaeck. The key insight of this Article is
to treat processes as another form of species into which a generic
claim can be decomposed. Recognition that every product claim is
really a genus of processes adds another dimension to the space in
which the unpredictability of the art can play a role. The Article
221. See also supra Parts II.C & IID.
222. Such evidence can be submitted to the USPTO via Rule 132 affidavits. See supra
note 26 and accompanying text.
223. See Sean B. Seymore, The Teaching Function of Patents, 85 NOTRE DAME L.
REv. 621 (2010); Seymore, Heightened Enablement in the Unpredictable Arts, supra note
30.
224. Cf O'Reilly v. Morse, 56 U.S. 62 (1854); In re Moore, 439 F.2d 1232, 1236
(C.C.P.A. 1971) ("The relevant inquiry may be summed up as being whether the scope of
enablement provided to one of ordinary skill in the art by the disclosure is such as to be
commensurate with the scope of protection sought by the claims.").
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shows the importance of evaluating the genus of processes for making
a claimed product in the context of the enablement inquiry, as
performed through the underlying analyses of whether claim breadth
is in "reasonable correlation" to the disclosures of the specification
and of whether the specification teaches those skilled in the art to
practice the subject matter of the invention without "undue
experimentation." In addition, the Article advances a workable
proposal for encouraging changes in claiming practice that can help
foster compliance with the enablement requirement of § 112 1 1.
Several Federal Circuit decisions of the past two decades have
shown discomfort with broad claims of biotechnology.2  One judicial
innovation for invalidating broad biotechnology patents is the
application of the written description requirement to originally filed
claims. 226 Although this line of cases has been vigorously criticized by
a number of scholars,2 the Federal Circuit has recently affirmed the
existence of the written description requirement and its potential
application to originally filed claims in an en banc decision.28
Another approach for cabining the claims directed to the subject
matter of biotechnology is to limit the scope of the claims to
embodiments known at the time of the filing,229 but this proposal runs
into conflict with the venerable doctrine of allowing the patentee to
capture some of the upside from unforeseeable after-arising
225. See, e.g., Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004);
Regents of the University of California v. Eli Lilly & Co., 119 F.3d 1559 (Fed. Cir. 1997);
Genentech, Inc. v. Novo Nordisk, A/S, 108 F.3d 1361 (Fed. Cir. 1997); Fiers v. Revel, 984
F.2d 1164 (Fed. Cir. 1993); In re Wright, 999 F.2d 1557, 1561 (Fed. Cir. 1993); In re Vaeck,
947 F.2d 488 (Fed. Cir. 1991); Amgen, Inc. v. Chugai Pharm. Co., Ltd., 927 F.2d 1200 (Fed.
Cir. 1991), cert. denied, 502 U.S. 856 (1991).
226. Rochester, 358 F.3d 916; Eli Lilly, 119 F.3d 1559; see also Enzo Biochem, Inc. v.
Gen-Probe, Inc., 296 F.3d 1316 (Fed. Cir. 2002).
227. See, e.g., Jeffie A. Kopczynski, Note, A New Era For § 112? Exploring Recent
Developments in the Written Description Requirement as Applied to Biotechnology
Inventions, 16 HARV. J.L. & TECH. 229 (2002); Janice M. Mueller, The Evolving
Application of the Written Description Requirement to Biotechnological Inventions, 13
BERKELEY TECH. L.J. 615 (1998); Karen G. Potter, Getting Written Description Right in
the Biotechnology Arts: A Realist Approach to Patent Scope, 28 BIOTECHNOLOGY L. REP.
1 (2009); see also Dan L. Burk & Mark A. Lemley, Is Patent Law Technology-Specific?, 17
BERKELEY TECH. L.J. 1155 (2002) (suggesting that the written description requirement is
enforced more rigorously for biotechnology patents than for patents in other areas of
technology, particularly software).
228. Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (en banc).
229. See Robin Feldman, Rethinking Rights in Biospace, 79 S. CAL. L. REV. 1, 40-41
(2005).
7 - KARSHTIED 11.19 (Do NoT DELETE) 11/20/2010 2:29 PM
WINTER 2011] HARD-TO-REPRODUCE INVENTIONS 155
technologies that fall within the literal scope of its claims .23) Finally,
some commentators have suggested doing away with the doctrine that
211treats "natural extracts" as patentable subject matter. Such a
prohibition, however, contravenes well-established caselaw,232 and, in
any case, probably would not apply to synthetic proteins made using
engineered cells.
In contrast, the approach outlined herein relies on the
enablement doctrine, which is less controversial than the written
description doctrine,2 3 attempts to achieve consistency with recent
Federal Circuit case law dealing with the enablement requirement,2 4
and applies the holding of a recent case that clarified the status of
process limitations in infringement analysis. Moreover, the
approach of this Article is consistent with the doctrine that claims
may be invalid for lack of enablement if they read on a large number
of inoperative embodiments.236 Most importantly, however, this
Article strives to help make the enablement doctrine of patent law
more consonant with the research community's requirements of
operability and verifiability, which themselves are based on the
fundamental norm of reproducibility.
230. See United States Steel Corp. v. Phillips Petroleum Co., 865 F.2d 1247 (Fed. Cir.
1989); In re Hogan, 559 F.2d 595 (C.C.P.A. 1977).
231. See, e.g., Allen K. Yu, Why It Might Be Time to Eliminate Genomic Patents,
Together with the Natural Extracts Doctrine Supporting Such Patents, 47 IDEA 659 (2007);
see also Liivak, supra note 55.
232. See Diamond v. Chakrabarty, 447 U.S. 303 (1980); Parke-Davis & Co. v. H.K.
Mulford Co., 189 F. 95 (C.C.S.D.N.Y. 1911). But see Ass'n for Molecular Pathology v.
USPTO, 702 F. Supp. 2d 181 (S.D.N.Y. 2010) (invalidating patent claims to DNA
containing breast cancer susceptibility genes).
233. See generally Robin C. Feldman, The Inventor's Contribution, 2005 UCLA J.L. &
TECH. 6 (2005).
234. See Sitrick v. Dreamworks, LLC, 516 F.3d 993, 1000 (Fed. Cir. 2008); Auto. Techs.
Int'l, Inc. v. BMW of N. Am., Inc., 501 F.3d 1274 (Fed. Cir. 2007); Liebel -Flarsheim Co. v.
Medrad, Inc., 481 F.3d 1371 (Fed. Cir. 2007); Plant Genetic Sys., N.V. v. DeKalb Genetics
Corp., 315 F.3d 1335 (Fed. Cir. 2003); AK Steel Corp. v. Sollac and Ugine, 344 F.3d 1234
(Fed. Cir. 2003).
235. Sandoz, 566 F.3d at 1291.
236. MPEP § 2164.08(b); see also Atlas Powder Co. v. E.I. Du Pont de Nemours & Co.,
750 F.2d 1569, 1577 (Fed. Cir. 1984); In re Cook, 439 F.2d 730, 735 (C.C.P.A. 1971). For a
recent decision invalidating a patent on enablement grounds by employing the inoperative
embodiments reasoning, see Pharm. Resources, Inc. v. Roxane Labs., Inc., Nos. 2007-1093,
2007-1134, 253 Fed. Appx. 26, 2007 (Fed. Cir. 2007). In the Article, I approached the
question of inoperative embodiments through the lens of the undue experimentation
inquiry, insofar as undue experimentation is required to select operative embodiments of
the disputed claim. See supra notes 119 & 155 and accompanying text.
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